More Diseño Web © Carlos Guillen - September 5th 2012!

Publications

Books and monographs published:

  1. Shah NV, Houston SK, Markoe AM, Feuer W, Murray TG. Early SD-OCT diagnosis
    followed by prompt treatment of radiation maculopathy using intravitreal bevacizumab maintains functional visual acuity. Clin Ophthalmol. 2012;6:1739-48. doi: 10.2147/OPTH.S34949. Epub 2012 Oct 29. PubMed PMID: 23152651; PubMed Central PMCID: PMC3497449.
  2. Steven Houston SK, Shah NV, Murray TG. Intraoperative ultrasonography AIDS plaque positioning. Ophthalmology. 2012 Nov;119(11):2419-20. doi: 10.1016/j.ophtha.2012.07.043. PubMed PMID: 23122476.
  3. Aziz HA, Lasenna CE, Vigoda M, Fernandes C, Feuer W, Aziz-Sultan MA, Murray TG. Retinoblastoma treatment burden and economic cost: impact of age at diagnosis and selection of primary therapy. Clin Ophthalmol. 2012;6:1601-6. doi: 10.2147/OPTH.S33094. Epub 2012 Oct 4. PubMed PMID: 23055684; PubMed Central PMCID: PMC3468280.
  4. Parke DW 3rd, Sisk RA, Murray TG. Intraoperative intravitreal triamcinolone decreases macular edema after vitrectomy with phacoemulsification. Clin Ophthalmol. 2012;6:1347-53. doi: 10.2147/OPTH.S34653. Epub 2012 Aug 17. PubMed PMID: 22969279; PubMed Central PMCID: PMC3429292.
  5. Henry CR, Berrocal AM, Hess DJ, Murray TG. Intraoperative spectral-domain optical coherence tomography in coats' disease. Ophthalmic Surg Lasers Imaging. 2012 Jul 26;43:e80-4. doi: 10.3928/15428877-20120719-01. PubMed PMID: 22827477.
  6. Wetters NG, Murray TG., Moric M, Sporer SM, Paprosky WG, Della Valle CJ. Risk Factors for Dislocation After Revision Total Hip Arthroplasty. Clin Orthop Relat Res. 2012 Sep 7. [Epub ahead of print] PubMed PMID: 22956236.
  7. Parke DW 3rd, Sisk RA, Houston SK, Murray TG. Ocular hypertension after intravitreal triamcinolone with vitrectomy and phacoemulsification. Clin Ophthalmol. 2012;6:925-31. doi: 10.2147/OPTH.S32934. Epub 2012 Jun 18. PubMed PMID: 22791974; PubMed Central PMCID: PMC3392914.
  8. Sisk RA, Riemann CD, Petersen MR, Foster RE, Miller DM, Murray TG., Augsburger JJ. FUNDUS AUTOFLUORESCENCE FINDINGS OF CHOROIDAL OSTEOMA. Retina. 2012 Jun 20. [Epub ahead of print] PubMed PMID: 22718153.
  9. Piña Y, Houston SK, Murray TG., Koru-Sengul T, Decatur C, Scott WK, Nathanson L, Clarke J, Lampidis TJ. Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LH(BETA)T(AG) retinal tumors. Clin Ophthalmol. 2012;6:817-30. doi: 10.2147/OPTH.S29688. Epub 2012 May 29. PubMed PMID: 22701083; PubMed Central PMCID: PMC3373226.
  10. Aziz HA, Berrocal AM, Sisk RA, Hartley K, Diaz-Barbosa M, Johnson RA, Hess D, Dubovy SR, Murray TG., Flynn HW Jr. Intraocular infections in the neonatal intensive care unit. Clin Ophthalmol. 2012;6:733-7. doi: 10.2147/OPTH.S26362. Epub 2012 May 14. PubMed PMID: 22654500; PubMed Central PMCID: PMC3363318.
  11. Leung E, Diaz-Barbosa M, Alabiad C, Hodapp E, Tse D, Murray TG., Castaner JC, Martin D, Berrocal AM. Prenatal ultrasonographic detection of ophthalmic diseases. J Pediatr Ophthalmol Strabismus. 2012 May 22;49:e26-9. doi: 10.3928/01913913-20120515-02. PubMed PMID: 22624614.
  12. Murray TG., Wetters NG, Moric M, Sporer SM, Paprosky WG, Della Valle CJ. The use of abduction bracing for the prevention of early postoperative dislocation after revision total hip arthroplasty. J Arthroplasty. 2012 Sep;27(8 Suppl):126-9. doi: 10.1016/j.arth.2012.03.030. Epub 2012 May 17. PubMed PMID: 22608688.
  13. Shah NV, Houston SK, Murray TG., Markoe AM. Evaluation of the surgical learning curve for I-125 episcleral plaque placement for the treatment of posterior uveal melanoma: a two decade review. Clin Ophthalmol. 2012;6:447-52. doi: 10.2147/OPTH.S30307. Epub 2012 Mar 20. PubMed PMID: 22536035; PubMed Central PMCID: PMC3334212.
  14. Bielory BP, Dubovy SR, Sinclair JC, Wykoff C, Murray TG.. Pseudohypopyon as a clinical manifestation in metastatic lung carcinoma. Ophthalmic Surg Lasers Imaging. 2012 Feb 9;43 Online:e1-4. doi: 10.3928/15428877-20120130-01. PubMed PMID: 22320830.
  15. Houston SK, Wykoff CC, Berrocal AM, Hess DJ, Murray TG.. Lasers for the treatment of intraocular tumors. Lasers Med Sci. 2012 Feb 3. [Epub ahead of print] PubMed PMID: 22302638.
  16. Piña Y, Decatur C, Murray TG., Houston SK, Lopez-Cavalcante M, Hernandez E, Celdran M, Shah N, Feuer W, Lampidis T. Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LH(BETA)T(AG) retinal tumors. Invest Ophthalmol Vis Sci. 2012 Feb 27;53(2):996-1002. doi: 10.1167/iovs.11-8265. Print 2012 Feb. PubMed PMID: 22266512; PubMed Central PMCID: PMC3317436.
  17. Silva RA, Dubovy SR, Fernandes CE, Hess DJ, Murray TG.. Retinoblastoma with Coats' response. Ophthalmic Surg Lasers Imaging. 2011 Dec 16;42 Online:e139-43. doi: 10.3928/15428877-20111208-04. PubMed PMID: 22165951.
  18. Houston SK, Wykoff CC, Berrocal AM, Hess DJ, Murray TG.. Laser treatment for retinopathy of prematurity. Lasers Med Sci. 2011 Dec 2. [Epub ahead of print] PubMed PMID: 22134790.
  19. Shirodkar AR, Pathengay A, Flynn HW Jr, Albini TA, Berrocal AM, Davis JL, Lalwani GA, Murray TG., Smiddy WE, Miller D. Delayed- versus acute-onset endophthalmitis after cataract surgery. Am J Ophthalmol. 2012 Mar;153(3):391-398.e2. doi: 10.1016/j.ajo.2011.08.029. Epub 2011 Oct 25. PubMed PMID: 22030353; PubMed Central PMCID: PMC3381653.
  20. Sinclair JC, Gold AS, Murray TG.. Bilateral choroidal metastases from primary esophageal melanoma: a rare case. Optom Vis Sci. 2012 Apr;89(4):502-6. doi: 10.1097/OPX.0b013e318249d61b. PubMed PMID: 22282224.

Juried or refereed journal articles and exhibitions:

  1. Bielory BP, Dubovy SR, Sinclair JC, Wykoff C, Murray TG. Pseudohypopyon as a clinical manifestation in metastatic lung carcinoma. 2012 Feb 9;43:e1-4. doi: 10.3928/15428877-20120130-01. PMID: 22320830 [PubMed - in process]
  2. Houston SK, Wykoff CC, Berrocal AM, Hess DJ, Murray TG. Lasers for the treatment of intraocular tumors. Lasers Med Sci. 2012 Feb 3. [Epub ahead of print]
  3. Sinclair JC, Gold AS, Murray TG. Bilateral choroidal metastases from primary esophageal melanoma: a rare case. Optom Vis Sci. 2012 Apr;89(4):502-6.
  4. Piña Y, Decatur C, Murray TG, Houston SK, Lopez-Cavalcante M, Hernandez E, Celdran M, Shah N, Feuer W, Lampidis T. Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LH(BETA)T(AG) retinal tumors. Invest Ophthalmol Vis Sci. 2012 Feb 27;53(2):996-1002. doi: 10.1167/iovs.11-8265. Print 2012 Feb.
  5. Silva RA, Dubovy SR, Fernandes CE, Hess DJ, Murray TG.  Retinoblastoma With Coats’ Response. Ophthalmic Surg Lasers Imaging. 2011 Dec 16;42:e139-43. doi: 10.3928/15428877-20111208-04. PMID: 22165951 [PubMed - in process]
  6. Houston SK, Wykoff CC, Berrocal AM, Hess DJ, Murray TG.  Laser treatment for retinopathy of prematurity.  Laser treatment for retinopathy of prematurity.  Lasers Med. Sci. 2011 Dec. 2 [Epub ahead of print]
  7. Shirodkar AR, Pathengay A, Flynn HW Jr, Albini TA, Berrocal AM, Davis JL, Lalwani GA, Murray TG, Smiddy WE, Miller D. Delayed-Versus Acute-Onset Endophthalmitis After Cataract Surgery.  Am J Ophthalmol. 2011 Oct 24. [Epub ahead of print]
  8. Houston SK, Murray TG. Microarry gene-expression analysis in ocular oncology:  uveal melanoma and retinoblastoma. Expert Rev. Ophthalmol. 2011 6(4), 477-485
  9. Houston SK, Markoe AM, Boldt HC, Murray TG. Juxtapapillary Uveal Melanomas Patient Outcomes After Treatment With Proton Irradiation for Peripapillary and Parapapillary Melanomas. Arch Ophthalmol. 2011 Sept;129 (9):1218-1220.
  10. Khan S, Finger PT, Yu GP, Razzaq L, Jager MJ, Keizer RJ, Sandkull P, Seregard S, Gologorsky D, Schefler AC, Murray TG, Kivela¨T, Giuliari GP, McGowan H, Simpson ER, Corriveau C, Coupland SE, Damato BE.  Clinical and Pathologic Characteristics of Biopsy-Proven Iris Melanoma. Arch Ophthalmol. Published online September 12, 2011.doi:10.1001/archophthalmol.2011.286
  11. Murray TG, Tornambe P, Dugel P, Tong KB. Evaluation of economic efficiencies in clinical retina pratice: activity-based cost analysis and modeling to determine impacts of changes. Clin Ophthalmol. 2011: July; 5:913-925.
  12. Aziz HA, Berrocal AM, Sisk RA, Murray TG. Idiopathic infantile chronic rhegmatogenous retinal detachment. Ophthalmic Surg Lasers Imaging. 2011 Jul 14;42 Online:e63-4. doi: 10.3928/15428877-20110707-02.
  13. Wykoff CC, Murray TG, Markoe AM, Feun LG, Schefler AC, Gayer S. Preoperative Evaluation for Patients with Choroidal/Ciliary Body Melanomas:  What Is Necessary? Am J Ophthalmol. 2011 June;151(6): 921-924.
  14. Emanuelli A, Lalwani GA, Shane T, Murray TG, Berrocal AM. Widefield Fluorescein Angiography in Pediatric Retinal Diseases: The Next Frontier. Retina Today. 2011 May/June.
  15. Houston SK, Murray TG, Fernandes CE, Aziz-Sultan MA. Intra-arterial Chemotherapy for Retinoblastoma: A promising treatment modality, with eyes and lives being saved. Retinal Physician May 2011, 17-20.
  16. Moshfeghi AA, Rosenfeld PJ, Flynn HW Jr, Schwartz SG, Davis JL, Murray TG, Smiddy WE, Berrocal AM, Dubovy SR, Lee WH, Albini TA, Lalwani GA, Kovach JL, Puliafito CA. Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: a six-year experience at a university referral center. Retina. 2011 Apr;31(4):662-8.
  17. Houston SK, Berrocal AM, Murray TG. The future of diagnostic imaging in retinoblastoma. J Pediatr Ophthalmol Strabismus. 2011 April;15: 125-126.  
  18. Vigoda M, Latiff A, Murray T, Tutiven J, Berrocal A, Gayer S. Can children undergoing ophthalmologic examinations under anesthesia be safely anesthetized without using an IV line? Clin Ophthalmol. 2011: April; 5:503 – 508. DOI 10.2147/OPTH.S18605
  19. Houston SK, Markoe A, Boldt H, Murray TG.  Juxtapapillary Uveal Melanomas – Between a Rock and a Hardplace” – Patient Outcomes after Treatment with Proton Irradiation for Peripapillary and Parapapillary Melanomas. Arch Ophthalmol. In Press.
  20. Houston SK, Piña Y, Murray TG, Boutrid H, Cebulla C, Schefler AC, Shi W, Celdran M, Feuer W, Merchan J, Lampidis TJ. Novel retinoblastoma treatment avoids chemotherapy: the effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LH(BETA)T(AG) retinoblastoma tumors. Clin Ophthalmol. 2011: January; 5:129-137.
  21. Peterson EC, Elhammady MS, Quintero-Wolfe S, Murray TG, Aziz-Sultan MA. Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: initial experience with 17 tumors. J Neurosurg. 2011 Feb 4.
  22. Mutapcic L, Murray TG, Aziz-Sultan MA, Schefler AC, Quintero Wolfe S, Hess D,      Fernandes CE, Dubovy SR. Supraselective Intra-Arterial Chemotherapy: Evaluation of   Treatment Related Complications in Advanced Retinoblastoma. Clin Ophthalmol. 2011: February, 5:171-176.
  23. Boutrid H, Wolfe SQ, Murray TG, Aziz-Sultan MA, Pina Y, Moftakhar R, Fernandes CE, Reichback J. Bilateral Orbital Vasculature Alterations Following Systemic Chemotherapy and External Beam Radiation Therapy Treatment of Advanced Retinoblastoma: Implications for Intra-arterial Chemotherapy Management.  Retinal Cases Brief Reports 5:124–127, 2011.
  24. Houston, SK, Murray TG, Pina Y, Decatur C, Cavalcante L, Markoe AM. Pharmacotherapy for Radiation Retinopathy. Retina Today. 2010 Nov/Dec.
  25. Bayraktar S, Stefanovic A, Montague N, Davis J, Murray TG, Lossos IS. Central nervous system manifestations of marginal zone B-cell lymphoma. Ann Hematol 2010 89:1003-1009
  26. Suk KK, Berrocal AM, Murray TG, Rich R, Major JC, Hess D, Johnson RA. Retinal detachment despite aggressive management of aggressive posterior retinopathy of prematurity. J Pediatr Ophthalmol Strabismus. 2010 Dec 22;47.
  27. Priest JR, Williams GM, Manera R, Jenkinson H, Bründler MA, Davis S, Murray TG, Galliani CA, Dehner LP. Ciliary body medulloepithelioma: four cases associated with pleuropulmonary blastoma–a report from the International Pleuropulmonary Blastoma Registry.  Br J Ophthalmol. 2010 Dec 13.
  28. Vajzovic LM, Murray TG, Aziz-Sultan MA, Schefler AC, Fernandes CE, Wolfe SC, Hess DJ, Dubovy SR. Clinicopathologic review of enucleated eyes after intra-arterial chemotherapy with melphalan for advanced retinoblastoma.   Arch Ophthalmol. 2010 Dec;128(12):1619-23.
  29. Piña Y, Houston SK, Murray TG, Boutrid H, Celdran M, Feuer W, Shi W, Hernandez E, Lampidis TJ. Focal, periocular delivery of 2-deoxy-D-glucose as adjuvant to chemotherapy for treatment of advanced retinoblastoma.  Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6149-56.
  30. Houston SK, Murray TG, Wolfe SQ, Fernandes CE. Current update on retinoblastoma. Int Ophthalmol Clin. 2011 Winter;51(1):77-91.
  31. Sisk RA, Berrocal AM, Albini TA, Murray TG. Bevacizumab for the treatment of pediatric retinal and choroidal diseases. Ophthalmic Surg Lasers Imaging. 2010 Nov 1;41(6):582-92.
  32. Merchan JR, Kovács K, Railsback JW, Kurtoglu M, Jing Y, Piña Y, Gao N, Murray TG, Lehrman MA, Lampidis TJ. Antiangiogenic activity of 2-deoxy-D-glucose. PLoS One. 2010 Oct 27;5(10):e13699.
  33. Piña Y, Boutrid H, Murray TG, Wolfe SQ, Schefler AC, Houston SS, Moftakhar R, Fernandes CE, Reichbach J, Aziz HA, Markoe AM, Aziz-Sultan MA.  Ophthalmic Vasculature Alterations Following Systemic Chemotherapy and Periocular Carboplatin Treatment of Advanced Retinoblastoma. J Pediatr Ophthalmol Strabismus. 2010 Sep 22;47.
  34. Gold AS, Nguyen JT, Murray TG: Macular Hole Secondary to Capillary Hemangioblastoma. Optom Vis Sci. 2010 Sep;87(9).
  35. Williams BK Jr, Schefler AC, Garonzik SN, Gologorsky D, Shi W, Cavalcante LL, Cavalcante ML, Feuer WJ, Murray TG. Frequent Prosthesis Refitting to Prevent Implant Exposure in Patients with Retinoblastoma. J Pediatr Ophthalmol Strabismus. 2010 Aug 23:1-9.
  36. Sisk RA, Murray TG. Combined phacoemulsification and sutureless 23-gauge pars plana vitrectomy for complex vitreoretinal diseases. Br J Ophthalmol. 2010 Aug;94(8):1028-32.
  37. Gologorsky D, Schefler AC, Ehlies FJ, Raskauskas PA, Pina Y, Williams BK, Murray TG. Clinical imaging and high-resolution ultrasonography in melanocytoma management. Clin Ophthalmol. 2010 Aug 9;4:855-9.
  38. Davis RP, Schefler AC, Murray TG. Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration. Clin Ophthalmol. 2010 Jul 30;4:703-7.
  39. Jacobs DJ, Murray TG, Cubillas AV. Gaze-evoked vitreous hemorrhage in choroidal melanoma. Retina. 2010 Jul-Aug;30(7):1159.
  40. Cavalcante LL, Cavalcante ML, Murray TG, Vigoda MM, Piña Y, Decatur CL, Davis RP, Olmos LC, Schefler AC, Parrott MB, Alliman KJ, Flynn HW, Moshfeghi AA. Intravitreal injection analysis at the Bascom Palmer Eye Institute: evaluation of clinical indications for the treatment and incidence rates of Endophthalmitis. Clin Ophthalmol. 2010:4 May 25;4:519-24.
  41. Aziz HA, Sisk RA, Berrocal AM, Murray TG.  Optic nerve aplasia in aicardi syndrome. J Pediatr Ophthalmol Strabismus. 2010 May 21;47:e1-4.
  42. Leng T, Cebulla CM, Schefler AC, Murray TG. Focal periocular carboplatin chemotherapy avoids systemic chemotherapy for unilateral, progressive retinoblastoma. Retina. 2010 Apr;30(4 Suppl):S66-8.
  43. Sisk RA, Berrocal AM, Murray TG, Mavrofrides EC. Extended Endotamponade with Perfluoro-n-Octane in Pediatric Retinal Detachment. Ophthalmic Surg Lasers Imaging. 2010 Mar 9:1-3.
  44. Aziz HA, Boutrid H, Murray TG, Berrocal A, Wolfe SQ, Pina Y, Dorfman M, Moftakhar R, Fernandes CE, Reichbach J, Aziz-Sultan MA. Supraselective injection of intraarterial melphalan as the primary treatment for late presentation unilateral multifocal stage Vb retinoblastoma. Retina. 2010 Apr;30(4 Suppl):S63-5.
  45. Raveesh M, Shanmugam MP, Murray TG. Diagnostic and therapeutic challenges. Retina. 2010 May;30(5):832-5.
  46. Cebulla CM, Ruggeri M, Murray TG, Feuer WJ, Hernandez E. Spectral domain optical coherence tomography in a murine retinal detachment model. Exp Eye Res.2010 Apr;90(4):521-7. Epub 2010 Jan 28.
  47. Bajenaru ML, Pina Y, Murray TG, Cebulla CM, Feuer W, Jockovich ME, Marin Castano ME. Gelatinase expression in retinoblastoma: modulation of LH(BETA)T(AG) retinal tumor development by anecortave acetate. Invest Ophthalmol Vis Sci. 2010 Jun;51(6):2860-4. Epub 2010 Jan 27.
  48. Pina Y, Boutrid H, Murray TG, Jager MJ, Cebulla CM, Schefler A, Ly LV, Alegret A, Celdran M, Feuer W, Jockovich ME. Impact of tumor-associated macrophages in LH(BETA)T(AG) mice on retinal tumor progression: relation to macrophage subtype. Invest Ophthalmol Vis Sci. 2010 May;51(5):2671-7. Epub 2010 Jan 6.
  49. Williams BK, Cebulla CM, Schefler AC, Fernandes CE, Gologorsky D, Murray TG. Required reduction in dose of chemotherapy for retinoblastoma due to down syndrome-associated chemosensitivity. Retinal Cases Brief Reports: 4:59-61, 2010
  50. Wester ST, Murray TG. Retinal Arteriovenous Malformation Presenting with Retinal Vein Occlusion During Pregnancy. Retinal Cases & Brief Reports: 4:112-115, 2010
  51. Rich R, Vanderveldt S, Berrocal AM, Mavrofrides EC, Murray TG, Gregori N. Treatment of choroidal neovascularization associated with Best’s disease in children. J Pediatr Ophthalmol Strabismus. 2009 Sep-Oct;46(5):306-11.
  52. Seider MI, Lujan BJ, Gregori G, Jiao S, Murray TG, Puliafito CA. Ultra-high resolution spectral domain optical coherence tomography of traumatic maculopathy. Ophthalmic Surg Lasers Imaging. 2009 Sep-Oct;40(5):516-21. doi: 10.3928/15428877-20090901-16. Erratum in: Ophthalmic Surg Lasers Imaging. 2010 Jan-Feb;41(1):144.
  53. Patel PD, Klika AK, Murray TG, Elsharkawy KA, Krebs VE, Barsoum WK. Influence of Technique With Distally Fixed Modular Stems in Revision Total Hip Arthroplasty. J  Arthroplasty. 2010 Sep;25(6):926-31.
  54. Barsoum WK, Murray TG, Klika AK, Green K, Miniaci SL, Wells BJ, Kattan MW. Predicting Patient Discharge Disposition After Total Joint Arthroplasty in the United States. J Arthroplasty. 2010 Sep;25(6):885-92.
  55. Stepien KE, Rosenfeld PJ, Puliafito CA, Feuer W, Shi W, Al-Attar L, Dubovy SR, Murray TG, Davis JL, Lee WH, Schwartz SG, Smiddy WE, Berrocal AM, Flynn HW Jr. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration. Retina. 2009 Sep;29(8):1067-73.
  56. Leng T, Schefler AC, Murray TG. Retinal vascular tumor and peripheral retinal vasculitis in the setting of systemic tuberculosis. Ophthalmic Surg Lasers Imaging. 2009 Jul-Aug;40(4):409-12.
  57. Leng T, Flynn HW Jr, Miller D, Murray TG, Smiddy WE. Endophthalmitis caused by proteus species: antibiotic sensitivities and visual acuity outcomes. Retina.  2009 Jul-Aug;29(7):1019-24.
  58. Gregori NZ, Rattan GH, Rosenfeld PJ, Puliafito CA, Feuer W, Flynn HW Jr, Berrocal AM, Al-Attar L, Dubovy S, Smiddy WE, Schwartz SG, Lee WH, Murray TG. Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion. Retina. 2009 Jul-Aug;29(7):913-25.
  59. Boutrid H, Pina Y, Cebulla CM, Feuer WJ, Lampidis TJ, Jockovich ME, Murray TG. Increased hypoxia following vessel targeting in a murine model of retinoblastoma. Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5537-43. Epub 2009 Jul 2.
  60. Sisk RA, Berrocal AM, Feuer WJ, Murray TG. Visual and Anatomic Outcomes With or Without Surgery in Persistent Fetal Vasculature. Ophthalmology. 2010 Nov;117(11):2178-83.
  61. Gologorsky D,  Schefler AC, Williams BK, Boutrid H, Dubovy SR,  Murray TG. Medulloepithelioma: Invasive versus Noninvasive Diagnostic Methods and their Impacts on Outcome. RETINAL Cases & Brief Reports. 5(1):33-36, Winter 2011
  62. Piña Y, Boutrid H, Schefler A, Dubovy S, Feuer W, Jockovich ME, Murray TG. Blood Vessel Maturation in Retinoblastoma Tumors: Spatial Distribution of Neovessels and Mature Vessels and Its Impact on Ocular Treatment. Invest. Ophthalmol. Vis. Sci. 2009 50(3): 1020-1024.
  63. Schefler AC, Berrocal AM, Murray TG. Advanced Coats’ disease. Management with repetitive aggressive laser ablation therapy. Retina. 2008 Mar;28(3 Suppl):S38-41. Erratum in: Retina. 2009 Jan;29(1):127.
  64. Wykoff CC, Dubovy SR, Barredo JC, Murray TG. Simultaneous Presentation of Retinoblastoma and Morning Glory Disk Anomaly. Retinal Cases & Brief Reports: 3:354-357, 2009.
  65. Piña Y, Cebulla CM, Murray TG, Alegret A, Dubovy SR, Boutrid H, Feuer W, Mutapcic L, and Jockovich ME. Blood Vessel Maturation in Human Uveal Melanoma: Spatial Distribution of Neovessels and Mature Vasculature. Ophthalmic Res. 2009; 41: 160-169.
  66. Ruggeri M, Tsechpenakis G, Jiao S, Jockovich ME, Cebulla C, Hernandez E, Murray TG, Puliafito CA. Retinal tumor imaging and volume quantification in mouse model using spectral-domain optical coherence tomography. Opt Express. 2009 Mar 2; 17(5):4074-83.
  67. Leng T, Schefler AC, Murray TG.  Retinal Vascular Tumor and Peripheral Retinal Vasculitis in the Setting of Systemic Tuberculosis.  Ophthalmic Surg Lasers Imaging. 2009 Jul-Aug;40(4):409-12.
  68. Schefler AC, Murray TG, Markoe A. Radiotherapy in Ocular Oncology: Advances in Brachytherapy for Uveal Melanoma. Retinal Physician, July/August 2009, 16-19.
  69. Cebulla CM, Alegret A, Ehlies FJ, Davis RP II, Hess DJ, CRA, the Echography Study Group, and Murray TG.  Echographic Localization of Periocular Carboplatin for Advanced Retinoblastoma. Retinal Cases Brief Reports. 2009;3: 4-7.
  70. Boutrid H, Pina Y, Cebulla CM, Feuer WJ, Lampidis TJ, Jockovich ME, Murray TG. Vessel Targeting Increases Hypoxia in a Murine Model of Retinoblastoma. Invest Ophthalmol Vis Sci. 2009;50(0)1-7.
  71. Alegret AM, Cebulla CM, Dubovy SR, Mutapcic L, Hess DJ, Murray TG. Photodynamic Therapy And Vitrectomy For A Large Optic Nerve Hemangioma With Neovascularization and Retinal Detachment: A Clinicopathologic Correlation. Retinal Cases Brief Reports. 2009;3:93-95.
  72. Schefler AC, Berrocal AM, Murray TG. Advanced Coats’ disease. Management with repetitive aggressive laser ablation therapy. Retina. 2008 Mar;28(3 Suppl):S38-41. Erratum in: Retina. 2009 Jan;29(1):127.
  73. Gaitan JR, Berrocal AM, Murray TG, Hess D, Johnson RA, Mavrofrides EC. Anterior segment ischemia following laser therapy for threshold retinopathy of prematurity. Retina. 2008 Mar;28(3 Suppl):S55-7. Erratum in: Retina. 2009 Jan;29(1):127.
  74. Couvillion SS, Wykoff CC, Tutiven JL, Schaefer AM, Murray TG. Diffuse Neonatal Hemangiomatosis Presenting as Bilateral Iris Hemangiomas in an Infant. Retinal Cases & Brief Reports: 3:279-282, 2009.
  75. Gregori NZ, Berrocal AM, Gregori G, Murray TG, Knighton RW, Flynn HW Jr, Dubovy S, Puliafito CA, Rosenfeld PJ. Macular spectral-domain optical coherence tomography in patients with X linked retinoschisis. Br J Ophthalmol. 2009 Mar;93(3):373-8. Epub 2008 Nov 19.
  76. Lalwani GA, Berrocal AM, Murray TG, Buch M, Cardone S, Hess D, Johnson RA, Puliafito CA. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina. 2008 Mar;28(3 Suppl):S13-8. Erratum in: Retina. 2009 Jan;29(1):127.
  77. Vigoda MM, Gayer S, Tutiven J, Mueller A, Murtha M, Schefler AC, Murray TG. Targeting operating room inefficiencies in the complex management of vision-threatening diseases in children. Arch Ophthalmol. 2008 Sep;126(9):1241-3.
  78. Cantrill HL, Pulido JS, Donaldson M, Shields CL, Murray TG. Diagnostic and therapeutic challenges. Retina. 2008 Jul-Aug;28(7):1018-22.
  79. Feilmeier MR, Lossos IS, Malumbres R, Schefler AC, Murray TG. Successful use of semi-nested PCR for the diagnosis of primary intraocular lymphoma. Leuk Lymphoma. 2008 Aug;49(8):1612-5.
  80. Hartley KL, Smiddy WE, Flynn HW Jr, Murray TG. Pars plana vitrectomy with internal limiting membrane peeling for diabetic macular edema. Retina. 2008 Mar;28(3):410-9.
  81. Lalwani GA, Flynn HW Jr, Scott IU, Quinn CM, Berrocal AM, Davis JL, Murray TG, Smiddy WE, Miller D. Acute-onset endophthalmitis after clear corneal cataract surgery (1996-2005). Clinical features, causative organisms, and visual acuity outcomes. Ophthalmology. 2008 Mar;115(3):473-6.
  82. Miller JJ, Scott IU, Flynn HW, Smiddy WE, Murray TG, Berrocal A, Miller D.  Endophthalmitis Caused by Bacillus Species. Am J Ophthalmol. 2008 May;145(5):883-8.
  83. Gregori NZ, Gaitan J, Rosenfeld PJ, Puliafito CA, Feuer W, Flynn HW Jr, Berrocal AM, Al-Attar L, Dubovy S, Smiddy WE, Schwartz SG, Lee WH, Murray TG. Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion. Retina. 2008 Oct;28(9):1325-37.
  84. Cebulla CM, Jockovich ME, Piña Y, Boutrid H, Alegret A, Kulak A, Hackam AS, Bhattacharya SK, Feuer WJ, Murray TG. Basic Fibroblast Growth Factor Impact on Retinoblastoma Progression and Survival. Invest Ophthalmol Vis Sci. 2008;49:5215-5221.
  85. Cebulla CM, Alegret AM, Feuer WJ, Shi W, Schefler AC, Murray TG. Tumor volume reduction using combined phacoemulsification and intravitreal triamcinolone injection for the management of cataract with treated uveal melanoma and atypical nevi.  J Cataract Refract Surg. 2008; 34(10):1669-73.
  86. Jockovich ME, Pina Y, Alegret A, Cebulla CM, Feuer W, Murray TG. Heterogeneous Tumor Vasculature in Retinoblastoma: Implications for Vessel Targeting Therapy. Retina. 2008.  28: S81-6.
  87. Alegret AM; Cebulla CM, Dubovy SR, Mutapcic L, Hess DJ, Murray TG. Pediatric Nasopharyngeal Carcinoma with Retinal Metastasis. Retinal Cases & Brief Reports. 3(1):8-11, Winter 2009.
  88. Cebulla CM, Alegret A, Feun L, Markoe AM, Hess DJ, Murray TG. Bilateral Ocular Manifestations of Aggressive Cutaneous Metastatic Melanoma. Retinal Cases Brief Reports. 2008;2(4):286-288.
  89. Jockovich ME, Suarez F, Alegret A, Piña Y, Hayden B, Cebulla C, Feuer W, Murray TG. Mechanism of retinoblastoma tumor cell death after focal chemotherapy, radiation, and vascular targeting therapy in a mouse model.  Invest Ophthalmol Vis Sci. 2007;48(12):5371-6.
  90. Boutrid H, Jockovich ME, Murray TG, Piña Y, Feuer WJ, Lampidis TL, Cebulla CM.  Targeting Hypoxia, a Novel Treatment for Advanced Retinoblastoma. Invest Ophthalmol Vis Sci. 2008;49:2799-2805.
  91. Cebulla CM, Jockovich ME, Boutrid H, Piña Y, Ruggeri M, Jiao S, Bhattacharya SK, Feuer WJ, Murray TG. Effects of SU1498, an Inhibitor of Vascular Endothelial Growth Factor Receptor-2, in a Transgenic Murine Model of Retinoblastoma. Open Ophthalmol J. 2008.2(1):62-67.
  92. Cebulla CM, Kleinerman RA, Alegret A, Kulak A, Dubovy SR, Hess DJ, Murray TG. Rapid Appearance of Rhabdomyosarcoma After Radiation and Chemotherapy for Retinoblastoma: a Clinicopathologic Correlation. Retinal Cases Brief Reports. Retinal Cases & Brief Reports: 2009 Fall;3(4):343-346.
  93. Cebulla CM, Alegret A, Lynn F, Markoe AM, Hess DJ, Murray TG. Bilateral ocular manifestations of aggressive cutaneous metastatic melanoma. Retinal Cases and Brief Report. 2008; 2:286-288.
  94. Bhatt AB, Schefler AC, Feuer WJ, Yoo SH, Murray TG. Comparison of Predictions Made by the Intraocular Lens Master and Ultrasound Biometry. Arch Ophthalmol. 2008;126(7):929-933.
  95. Schefler AC, Jockovich ME, Lossos IS, Toledano S, Feilmeier M, Murray TG.  Ocular tumors: update on pharmacology, therapeutics, and ocular imaging.  Retinal Physician.   Oct 2007; 37-44.
  96. Albano JD, Ward E, Jemal A, Anderson R, Cokkinides VE, Murray TG, Henley J, Liff  J, Thun MJ.  Cancer mortality in the United States by education level and race.  J Natl     Cancer Inst. 2007 Sept 19;99(18):1384-94.
  97. Gregori NZ, Flynn HW Jr, Miller D, Scott IU, Davis JL, Murray TG, Williams B Jr. Clinical features, management strategies, and visual acuity outcomes of Candida  endophthalmitis following cataract surgery.  Ophthalmic Surg Lasers Imaging.  2007      Sep-Oct;38(5):378-85.
  98. Miller DM, Murray TG, Suarez F, Cicciarelli NL, Swords GG.  Motility assessment      and clinical outcomes of a magnetically integrated microporous implant.  Ophthalmic Surg Lasers Imaging. 2007 Jul-Aug;38(4):339-41.
  99. Suarez F, Jockovich ME, Hernandez E, Feuer W, Parel JM, Murray TG: Paclitaxel in the Treatment of Retinal Tumors of LH beta-Tag Murine Transgenic Model of   Retinoblastoma.  Invest Ophthalmol Vis Sci. 2007 Aug;48(8):3437-40.
  100. Jockovich ME, Bajenaru ML, Pina Y, Suarez F, Feuer W, Fini ME, Murray TG: Retinoblastoma tumor vessel maturation impacts efficacy of vessel targeting in the LH(BETA)T(AG) mouse model.  Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2476-82.
  101. Schiedler V, Dubovy SR, Murray TG: Snare technique for enucleation of eyes with advanced retinoblastoma.  Arch Ophthalmol. 2007 May;125(5):680-3.
  102. Bosch JJ, Thompson JA, Srivastava MK, Iheagwara UK, Murray TG, Lotem M, Ksander BR, Ostrand-Rosenberg S.:  MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.  Cancer Res. 2007 May 1;67(9):4499-506.
  103. Jockovich ME, Murray TG, Clifford PD, Moshfeghi AA:  Posterior juxtascleral injection of anecortave acetate: magnetic resonance and echographic imaging and localization in rabbit eyes.  Retina. 2007 Feb;27(2):247-52.
  104. Schefler AC, Cicciarelli N, Feuer W, Toledano S, Murray TG: Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation. Ophthalmol 2007; 114 (1):162-169.
  105. Miller DM, Vedula AS, Flynn HW Jr, Miller D, Scott IU, Smiddy WE, Murray TG, Venkatraman AS. Endophthalmitis caused by staphylococcus epidermidis: in vitro antibiotic susceptibilities and clinical outcomes. Ophthalmic Surg Lasers Imaging. 2007 Nov-Dec;38(6):446-51.
  106. Schefler AC, Jockovich ME, Toledano S, Murray TG: Historical and modern approaches to chemotherapy for retinoblastoma:  A review.  Expert Review in Ophthalmology; 2006: 1: 83-95.
  107. Gregori NZ, Rosenfeld PJ, Puliafito CA, Flynn HW, Lee JE, Mavrofrides EC, Smiddy WE, Murray TG, Berrocal AM, Scott IU, Gregori G: One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion. Retina 2006; 26 (8):889-895.
  108. Murray TG: Commentary on “Diagnostic and Therapeutic Challenges,” submitted by: WW Lai, Y-s Zhou, DSC Lam. Retina 2006; 26:99-101.
  109. Murray TG, Sobrin, L: The case for observational management of suspected small choroidal melanoma. Arch Ophthalmol 2006; 124(9): 1344-1346.
  110. Hayden B, Jockovich M-E, Murray TG, Kralinger MT, Voigt M, Hernandez E, Feuer W, Parel J-M: Iontophoretic Delivery of Carboplatin in a Murine Model of Retinoblastoma. Invest Ophthalmolog Vis. Sci  2006; 47: 3717-3721.
  111. Jockovich M-E, Murray TG, Escalona- Benz E, Hernandez E, Feuer W: Anecortave Acetate as Single and Adjuvant Therapy in the Treatment of Retinal Tumors of LH BETA TAG Mice. Invest Ophthalmolog Vis. Sci  2006; 47: 1264-1268.
  112. Tell S, Yi H, Jockovich ME, Murray TG, Hackam AS: The Wnt signaling pathway has tumor suppressor properties in retinoblastoma. Biochemical & Biophysical Research Communications 2006; 349(1): 261-269.
  113. Callanan D, Scott IU, Murray TG, Oxford KW, Bowman CB, Flynn HW: Early onset endophthalmitis caused by Aspergillus species following cataract surgery. Am J Ophthalmol 2006; 142(3): 509-511.
  114. Mavrofrides EC, Berrocal AM, Murray TG: Development of multiple subretinal hemorrhages during diode laser supplementation for retinopathy of prematurity. J Pediatr Ophthalmol Strabismus 2006; 43(2):110-113.
  115. Lai WW, Zhou YS, Lam DS, Freeman WR, Chow DR, Murray TG: Diagnostic and therapeutic challenges.  Retina 2006; 26(1): 96-101.
  116. Hui JI, Murray TG: Radioactive plaque therapy. [Review] Int Ophthalmolog Clin 2006; 46(1): 51-68.
  117. Gregori NZ, Rosenfeld PJ, Puliafito CA, Flynn HW, Lee JE, Mavrofrides EC, Smiddy WE, Murray TG, Berrocal AM, Scott IU, Gregori G: One-year safety and efficacy of intravitreal triamcionolone acetonide for the management of macular edema secondary to central retinal vein occlusion. Retina 2006; 26(8): 889-895.
  118. Sobrin L, Schiffman JC, Markoe AM, Murray TG: Outcomes of iodine 125 plaque radiotherapy after initial observation of suspected small choroidal melanomas: a pilot study. Ophthalmol 2005; 112 (10): 1777-1783.
  119. Smiddy WE, Smiddy RJ, Ba’Arath B, Flynn HW, Murray TG, Feuer WJ, Miller D: Subconjuctival antibiotics in the treatment of endophthalmitis managed without vitrectomy. Retina 2005; 25(6): 751-758.
  120. Miller DM, Murray TG, Cicciarelli NL, Capo H, Markoe AM: Pars plana lensectomy and intraocular lens implantation in pediatric radiation –induced cataracts in retinoblastoma. Ophthalmol 2005; 112 (9): 1620-1624.
  121. Scott IU, Flynn HW, Murray TG, Smiddy WE, Davis JL, Feuer WJ: Outcomes of complex retinal detachment repair using 1000- vs 5000- centistokes silicone oil. Arch Ophthalmol 2005; 123(4): 473-478.
  122. Sobrin L, Dubovy SR, Davis JL, Murray TG:  Isolated, bilateral intraocular lymphoma in a 15 year old girl. Retina 2005; 25(3): 370-373.
  123. Couvillion SS, Margolis R, Mavrofrides E, Hess D, Murray TG: Laser Treatment of Coats’ Disease. Journal of Pediatric Ophthalmology & Strabismus 2005; 42:367-368.
  124. Smiddy WE, Smiddy RJ, Ba’Arath B, Flynn HW, Murray TG, Feuer WJ, Miller D: Subconjunctival antibiotics in the treatment of endophthalmitis managed without vitrectomy. Retina 2005; 25(6): 751-758.
  125. Escalona-Benz E, Jockovich ME, Murray TG, Hayden B, Hernandez E, Feuer W, Windle JJ:  Combretastatin A-4 prodrug in the treatment of a murine model of retinoblastoma.  Invest Ophthalmol Vis Sci 2005; 46(1):8-11.
  126. Conway RM, Wheeler SM, Murray TG, Jockovich ME, O’Brien JM:  Retinoblastoma: animal models.  Ophthalmol Clin North Am. 2005; 18(1):25-39.
  127. Miller DM, Benz MS, Murray TG, Dubovy SR: Intraretinal calcification and osseous metaplasia in Coats disease. Arch Ophthalmol 2004; 122:1710-1712.
  128. Margolis R, Couvillion SS, Mavrofrides EC, Hess D, Murray TG: Progression of familial exudative vitreoretinoapthy after laser treatment. Arch Ophthalmol 2004;122:1717-1718.
  129. Hayden BC, Jockovich ME, Murray TG, Voigt M, Milne P, Kralinger M, Feuer WJ, Hernandez E, Parel JM: Pharmacokinetics of systemic versus focal carboplatin chemotherapy in the rabbit eye: possible implication in the treatment of retinoblastoma.  Invest Ophthalmol Vis Sci 2004; 45:3644-3649.
  130. Benz MS, Escalona-Benz EM, Murray TG, Eifrig CWG, Yoder DM, Moore JK, Schiffman JC: Immediate postoperative use of a topical agent to prevent intraocular pressure elevation after pars plana vitrectomy with gas tamponade. Arch Ophthalmol 2004;122: 705-709.
  131. Treichel JL, Murray TG, Lewandowski MF, Stueven HA, Eells JT, Burke JM: Retinal toxicity in methanol poisoning. Retina 2004;24: 309-312.  [RPB Support]
  132. Sobrin L, Hayden BC, Murray TG, Cicciarelli N, Scott IU, Hernandez E, Wu X, Markoe AM, Feuer W, Fulton L, O’Brien JM: External beam radiation “salvage” therapy in transgenic murine retinoblastoma. Arch Ophthalmol 2004;122:251-257.
  133. Raja D, Benz MS, Murray TG, Escalona-Benz EM, Markoe A: Salvage external beam radiotherapy of retinal capillary hemangiomas secondary to von Hippel-Lindau disease: visual and anatomic outcomes. Ophthalmol 2004;111;150-153.
  134. Scott IU, Gorscak J, Gass JD, Feuer WJ, Murray TG:  Anatomic and visual acuity outcomes following thermal laser photocoagulation or photodynamic therapy for symptomatic circumscribed choroidal hemangioma with associated serous retinal detachment.   Ophthalmic Surg, Lasers & Imaging 2004;35(4):281-91.
  135. Chaudhry NA, Cohen KA, Flynn HW Jr, Murray TG: Combined pars plana vitrectomy and lens management in complex vitreoretinal disease. Seminars of Ophthalmol 2003;18(3)132-141.
  136. Moshfeghi DM, Kaiser PK, Scott IU, Sears JE, Benz M, Sinesterra JP, Kaiser RS, Bakri SJ, Maturi RK, Belmont J, Beer PM, Murray TG, Quiroz-Mercado H, Mieler WF: Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003;136:791-796.
  137. Escalona-Benz E, Benz MS, Murray TG, Hayden BC, Hernandez E, Garonzik SN, Cicciarelli NL: Magnetically integrated microporous implant. Safety and efficacy of secondary posting. Arch Ophthalmol 2003;121:1596-1600.
  138. Escalona-Benz E, Benz M, Briggs JW, Budenz DL, Parrish RK II, Murray TG: Uveal melanoma presenting as acute angle-closure glaucoma: Report of two cases. Am J Ophthalmol 2003;136:756-758.
  139. Scott IU, Flynn HW Jr, Murray TG, Feuer WJ: Outcomes of surgery for retinal detachment associated with proliferative vitreoretinopathy using perfluoro-n-octane: A multicenter study. Am J Ophthalmol 2003;136:454-463
  140. Sussman DA, Escalona-Benz E, Benz MS, Hayden BC, Feuer W, Cicciarelli N, Toledano S, Markoe A, Murray TG: Comparison of retinoblastoma reduction for chemotherapy vs external beam radiotherapy. Arch Ophthalmol 2003;121:979-984.
  141. Scott IU, Flynn HW Jr, Smiddy WE, Murray TG, Moore JK, Lemus DR, Feuer WJ: Clinical features and outcomes of pars plana vitrectomy in patients with retained lens fragments. Ophthalmol 2003;110:1567-1572.
  142. Moore JK, Scott IU, Flynn HW Jr, Smiddy WE, Murray TG, Kim JE, Vilar NF, Pereira MB, Jorge R: Retinal detachment in eyes undergoing pars plana vitrectomy for removal of retained lens fragments. Ophthalmology 2003;110:709-714.
  143. Scott IU, Lieb DF, Flynn HF Jr, Dessouki A, Murray TG, Miller D: Endophthalmitis caused by Mycobacterium chelonae: selection of antibiotics and outcomes of treatment.  Arch Ophthalmol 2003;121:573-576.
  144. Benz MS, Murray TG, Dubovy SR, Katz RS, Eifrig CWG: Endophthalmitis caused by Mycobacterium chelonae abcessus after intravitreal injection of triamcinolone. Arch Ophhalmol 2003;121;271-273.
  145. Sobrin L, Berrocal AM, Murray TG: Retinal detachment 7 years after prophylactic schisis cavity excision in juvenile x-linked retinoschisis. Ophthalmic Surg, Lasers & Imaging 2003;34:401-402.
  146. Scott IU, McCabe CM, Murray TG, Rosa RH Jr, Toledano S, Markoe AM: Eyelid and scleral necrosis following bare iridium-192 seed for retinoblastoma. Ophthalmic Surg, Lasers & Imaging 2003;34:324-326.
  147. Benz MS, Escalona-Caamano EM, Murray TG: Simultaneous presentation of retinopathy of prematurity and bilateral familial retinoblastoma in a premature infant. J Pediatr Ophthalmol Strabismus 2003;40:98-100.
  148. Chaudhry NA, Flynn HW Jr, Murray TG, Belfort A: Combined cataract surgery and vitrectomy for breakthrough vitreous hemorrhage from age-related macular degeneration. Ophthalmic Surg Lasers 2002;33:16-18.
  149. Song A, Dubovy SR, Berrocal AM, Murray TG: Endogenous fungal retinitis in a patient with acute lymphocytic leukemia manifesting as uveitis and optic nerve lesions. Arch Ophthalmol 2002;120:1754-1756.
  150. Scott IU, Murray TG, Flynn HW Jr, Feuer WJ, Schiffman JC, and the Perfluoron Study Group: Outcomes and complications associated with giant retinal tear management using perfluoro-n-octane. Ophthalmology 2002;109:1828-1833.
  151. Hayden BC, Murray TG, Cicciarelli N, Scott IU, Alexandridou A, Hernandez E, Wu X, Markoe AM, Feuer W, Fulton L, O’Brien JM: Hyperfractionated external beam radiation therapy in the treatment of murine transgenic retinoblastoma. Arch Ophthalmol 2002;120:353-359.
  152. Loo RH, Scott IU, Flynn HW Jr, Gass JDM, Murray TG, Lewis ML, Rosenfeld PJ, Smiddy WE: Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina 2002;22:19-24.
  153. Amirikia A, Scott IU, Capo H, Murray TG: Increasing hyperopia and esotropia as the presenting signs of bilateral diffuse choroidal hemangiomas in a patient with Sturge-Weber syndrome. J Ped Ophthalmol & Strab 2002;39:121-122.
  154. Davis JL, Miller D, Gonzales CA, Scott IU, Murray T: Reply to letter on Histoplasma capsulatum var. capsulatum. Ophthalmology 2002;109:218-219.
  155. Arroyave CP, Scott IU, Fantes FE, Feuer WJ, Murray TG: Corneal graft survival and intraocular pressure control after penetrating keratoplasty and glaucoma drainage device implantation. Ophthalmology 2001;108:1978-1985.
  156. Roth DB, Scott IU, Murray TG, Kaiser PK, Feuer WJ, Hughes JR, Rosa RH Jr.: Echography of retinoblastoma: histopathologic correlation and serial evaluation after globe-conserving radiotherapy or chemotherapy. J Pediatr Ophthalmol Strabismus 2001;38:136-143.
  157. Johnson RN, McDonald HR, Lewis H, Grand MG, Murray TG, Mieler WF, Johnson MW, Boldt HC, Olsen KR, Tornambe PE, Folk JC: Traumatic macular hole. Observations, pathogenesis, and results of vitrectomy surgery. Ophthalmology 2001;108:853-857.
  158. Duncan JL, Scott IU, Murray TG, Gombos DS, van Quill K, O’Brien JM: Routine neuroimaging in retinoblastoma for the detection of intracranial tumors. Arch Ophthalmol 2001;119:450-452.
  159. Corey RP, Scott IU, Flynn HW Jr, Rosa RH Jr, Murray TG: Surgical removal of submacular choroidal neovascularization: a clinicopathologic study and factors influencing outcomes. Ophthalmic Surg Lasers 2001;32:406-418.
  160. Parel J-M, Qiu H, Manns F, Fujiwara E, Lee W, Salas N, Hayden B, Lee E, Dubovy S, Murray TG: Experimental models for transcleral laser thermotherapy of ocular tumors. Florida Lions Eye Bank, 2001 Annual Report, pp.10-11.
  161. Amirikia A, Scott IU, Murray TG, Flynn HW Jr., Smiddy WE, Feuer WJ: Outcomes of vitreoretinal surgery for complications of branch retinal vein occlusion. Ophthalmology 2001;108:372-376; discussion by WF Mieler pp. 375-376, February.
  162. Smith JH, Murray TG, Fulton L, O’Brien JM: Siblings of retinoblastoma patients: are we underestimating their risk? Am J Ophthalmol 2000; 129(3): 396-398.
  163. Uusitalo MS, Van Quill KR, Scott IU, Matthay KK, Murray TG, O’Brien JM: Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination. Arch Ophthalmol 2001;119:41-48.
  164. Chaudhry N, Flynn HW Jr., Murray TG, Belfort A, Mello M Jr.: Combined cataract surgery and vitrectomy for recurrent retinal detachment. Retina 2000;20:257-261.
  165. Eells JT, Henry MM, Lewandowski MF, Seme MT, Murray TG: Development and characterization of a rodent model of methanol-induced retinal and optic nerve toxicity. Neurotoxicology 2000;21(3):321-330.
  166. Foster RE, Murray TG, Byrne SF, Hughes JR, Gendron BK, Ehlies FJ, Nicholson DH: Echographic features of medulloepithelioma. Am J Ophthalmol 2000;130:364-366.
  167. Scott IU, Moy CS, Murray TG for the COMS Group: Update on the Collaborative Ocular Melanoma Study (COMS) for the comprehensive ophthalmologist. Comprehensive Ophthalmol Update 2000;1:185-191.
  168. Hayden BH, Murray TG, Scott IU, Cicciarelli N, Hernandez E, Feuer W, Fulton L, O’Brien JM: Subconjunctival carboplatin in retinoblastoma. Arch Ophthalmol 2000;118:1549-1554.
  169. Amirikia A, Scott IU, Murray TG: Bilateral diffuse choroidal hemangiomas with unilateral facial nevus flammeus in Sturge-Weber syndrome. Am J Ophthalmol 2000;130:362-364.
  170. Anagnoste SR, Scott IU, Murray TG, Kramer D, Toledano S: Rhegmatogenous retinal detachment in retinoblastoma patients undergoing chemoreduction and cryotherapy. Am J Ophthalmol 2000;129:817-819.
  171. Murray TG, Cicciarelli NL, Croft BH, Garonzik S, Voigt M, Hernandez E: Design of a magnetically integrated microporous implant. Arch Ophthalmol 2000;118:1259-1262.
  172. Murray TG: Intraoperative echographic localization of iodine-125 episcleral plaque for brachytherapy of choroidal melanoma (reply to letter by PT Finger). Am J Ophthalmol 2000;130:540.
  173. Nakagawa N, Parel J-M, Murray TG, Oshima K: Effect of scleral shortening on axial length. Arch Ophthalmol 2000;118:965-968.
  174. Scott IU, Murray TG, Flynn HW Jr, Smiddy WE, Feuer WJ, Schiffman JC: Outcomes and complications associated with perfluoro-n-octane and perfluoroperhydrophenanthrene in complex retinal detachment repair. Ophthalmology 2000;107:860-865.
  175. Christmas NJ, Van Quill K, Murray TG, Gordon CD, Garonzik S, Tse D, Johnson T, Schiffman J, O’Brien JM: Evaluation of efficacy and complications. Primary pediatric orbital implants after enucleation. Arch Ophthalmol 2000;118:503-506.
  176. Gonzales CA, Scott IU, Chaudhry NA, Luu KM, Miller D, Murray TG, Davis JL: Endogenous endophthalmitis caused by Histoplasma capsulatum var. capsulatum. Ophthalmology 2000;107:725-729.
  177. Benz MS, Scott IU, Murray TG, Kramer D, Toledano S: Complications of systemic chemotherapy as treatment for retinoblastoma. Arch Ophthalmol 2000;118:577-578.
  178. Alexandrakis G, Scott IU, Flynn HW Jr, Murray TG, Feuer WJ: Visual outcomes with and without surgery in patients with persistent fetal vasculature. Ophthalmology 2000;107:1068-1072.
  179. Hasenyager Smith J, Murray TG, Fulton L, O’Brien JM: Siblings of retinoblastoma patients: are we underestimating their risk? Am J Ophthalmol 2000;129:396-398.
  180. Scott IU, Alexandrakis G, Flynn HW Jr, Smiddy WE, Murray TG, Schiffman J, Gedde SJ, Budenz DL, Fantes F, Parrish RK II: Combined pars plana vitrectomy and glaucoma drainage implant placement for refractory glaucoma. Am J Ophthalmol 2000;129:334-341.
  181. Amirikia A, Scott IU, Murray TG, Halperin LS: Acute bilateral visual loss associated with retinal hemorrhages following epiduroscopy. Arch Ophthalmol 2000;118:287-288.
  182. Tabandeh H, Chaudhry NA, Murray TG, Ehlies F, Hughes R, Scott IU, Markoe AM: Intraoperative echographic localization of Iodine-125 episcleral plaque for brachytherapy of choroidal melanoma. Am J Ophthalmol 2000;129:199-204.
  183. Chaudhry NA, Flynn HW Jr, Murray TG, Nicholson DN, Palmberg PF: Pars plana vitrectomy during cataract surgery for prevention of aqueous misdirection in high-risk fellow eyes. Am J Ophthalmol 2000;129:387-388.
  184. Chaudhry NA, Flynn HW Jr, Murray TG, Tabandeh H, Mello, MO Jr, Miller D: Emerging ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol 1999;128(4):509-5100.
  185. Scott IU, Moy CS, Murray TG, O’Brien JM: Issues in the diagnosis and management of small choroidal melanocytic lesions. Ocular Oncology 1999;2(2):149-157.
  186. Scott IU, Murray TG, Feuer WJ, Van Quill K, Markoe AM, Ling S, Roth DB, O’Brien JM: External beam radiotherapy in retinoblastoma: tumor control and comparison of 2 techniques. Arch Ophthalmol 1999; 117:766-770.
  187. Scott IU, Alexandrakis G, Cordahi GJ, Murray TG: Diffuse and circumscribed choroidal hemangiomas in a patient with Sturge-Weber syndrome. Arch Ophthalmol 1999;117:406-407.
  188. Gonzales CA, Scott IU, Chaudhry NA, Oster AS, Hess DJ, Murray TG: Bilateral rhegmatogenous retinal detachments with unilateral vitreous base avulsion as the presenting signs of child abuse. Am J Ophthalmol 1999;127:475-477.
  189. Henderer JD, Budenz DL, Flynn HW Jr, Schiffman JC, Feuer WJ, Murray TG: Elevated intraocular pressure and hypotony following silicone oil retinal tamponade for complex retinal detachment. Arch Ophthalmol 1999;117:1889-195.
  190. Scott IU, Murray TG, Toledano S, O’Brien JM: New retinoblastoma tumors in children undergoing systemic chemotherapy. Arch Ophthalmol 1998;116:1685-1686.
  191. Clark WL, Scott IU, Murray TG, Rosa RH Jr, Siatkowski RM, Langham MR Jr: Primary intraocular posttransplantation lymphoproliferative disorder. Arch Ophthalmol 1998;116:1667-1669.
  192. Murray TG: Cancer incidence after retinoblastoma: radiation dose and sarcoma risk (comment). Surv Ophthalmol 1998;43(3).
  193. Murray TG: Cancer incidence after retinoblastoma: radiation dose and sarcoma risk (comment). JAMA 1998.
  194. Christmas NJ, Gordon CD, Murray TG, Tse D, Johnson T, Garonzik S, O’Brien JM:  Intraorbital implants after enucleation and their complications: a 10-year review.  Arch Ophthalmol 1998;116(9):1199-1203.
  195. Scott IU, Murray TG, Hughes JR: Evaluation of imaging techniques for detection of extraocular extension of choroidal melanoma.  Arch Ophthalmol 1998;116(7):897-899.
  196. Gottlieb JL, Murray TG, Gass JDM: Low-dose external beam irradiation for bilateral diffuse choroidal hemangioma.  Arch Ophthalmol 1998;116(6):815-817.
  197. Kaiser PK, Murray TG, O’Brien JM: Laser photocoagulation of choroidal and retinal tumors (Review). Ophthalmic Surgery and Lasers 1998;29(1):59-78.
  198. Ksander BR, Geer DC, Chen PW, Salgaller ML, Rubsamen P, Murray TG: Uveal melanomas contain antigenically specific and non-specific infiltrating lymphocytes.  Current Eye Research 1998;17(2):165-173.
  199. Weishaar PD, Flynn HW Jr, Murray TG, Davis JL, Barr CC, Gross JG, Mein CE, McLean WC Jr, Killian JH: Endogenous Aspergillus endophthalmitis.  Clinical features and treatment outcomes.  Ophthalmology 1998;105(1):57-65.
  200. Murray TG: Small Choroidal Melanoma (editorial comment – review). Arch Ophthalmol 1997;115(12):1577-1578.
  201. Scott IU, Flynn HW Jr, Schiffman J, Smiddy WE, Murray TG, Ehlies F: Visual acuity outcomes among patients with appositional suprachoroidal hemorrhage. Ophthalmology 1997;104(12):2039-2046.
  202. Uno T, Chen PW, Murray TG, Podack ER, Ksander BR: Gene transfer of the CD80 costimulatory molecule into ocular melanoma cells using a novel episomal vector.  Invest Ophthalmol Vis Sci 1997;38(12):2531-2539.
  203. Murray TG, Cicciarelli N, McCabe CM, Ksander BR, Feuer W, Schiffman J, Mieler WF, O’Brien JM: In vitro efficacy of carboplatin and hyperthermia in a murine retinoblastoma cell line.  Invest Ophthalmol Vis Sci 1997;38(12):2516-2522.
  204. Verbik DJ, Murray TG, Tran JM, Ksander BR: Melanomas that develop within the eye inhibit lymphocyte proliferation.  Int J Cancer 1997;73(4):470-478.
  205. Murray TG, Cicciarelli N, O’Brien JM, Hernandez E, Mueller RL, Smith BJ, Feuer W.: Subconjunctival carboplatin therapy and cryotherapy in the treatment of transgenic murine retinoblastoma.  Arch Ophthalmol 1997;115(10):1286-1290.
  206. Chen PP, Weishaar PD, Murray TG: Blue rubber bleb nevus syndrome. J Pediatric Ophthalmol & Strabismus 1997;34(5):321-323.
  207. Chen PW, Murray TG, Uno T, Salgaller ML, Reddy R, Ksander BR.: Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease.  Clinical & Experimental Metastasis 1997;15(5):509-518.
  208. Murray TG, Steeves RA, Gentry L, Bresnick G, Boldt HC, Mieler WF, Tompkins D: Ferromagnetic hyperthermia: functional and histopathologic effects on normal rabbit ocular tissue. Int J Hyperthermia 1997;13(4):423-436.
  209. Chen PW, Murray TG, Salgaller ML, Ksander BR: Expression of MAGE genes in ocular melanoma cell lines.  J Immunotherapy, 1997;20(4):265-275.
  210. Vilar NF, Flynn HW Jr, Smiddy WE, Murray TG, Davis JL, Rubsamen PE: Removal of retained lens fragments after phacoemulsification reverses secondary glaucoma and restores visual acuity. Ophthalmology 1997;104(5):787-791; discussion 1997;104(5):791-792.
  211. Scott IU, O’Brien JM, Murray TG: Retinoblastoma: A review emphasizing genetics and management strategies. Seminars of Ophthalmology 1997;12:59-71.
  212. Rosenfeld P, Murray TG, Flynn HW Jr.,: Management of dislocated crystalline lens during clear-cornea phacoemulsification.  Annals of Ophthalmol 1997;29(1):7-10.
  213. Murray TG, Roth DB, O’Brien JM, Feuer W, Cicciarelli N, Markoe AM, Hernandez E, Smith BJ, Windle JJ: Local carboplatin and radiation therapy in the treatment of murine transgenic retinoblastoma.  Arch Ophthalmol 1996;114(11):1385-1389.
  214. Murray TG, O’Brien JM, Steeves RA, Smith BJ, Albert DM, Cicciarelli N, Markoe AM, Tompkins DT, Windle JJ: Radiation therapy and ferromagnetic hyperthermia in the treatment of murine transgenic retinoblastoma.  Arch Ophthalmol 1996;114(11):1376-1381.
  215. Eells JT, Salzman MM, Lewandowski MF, Murray TG: Formate-induced alterations in retinal function in methanol-intoxicated rats.  Toxicology & Applied Pharmacology 1996;140(1):58-69.
  216. Harbour JW, Murray TG, Byrne SF, Hughes JR, Gendron EK, Ehlies FJ, Markoe AM: Intraoperative echographic localization of iodine 125 episcleral radioactive plaques for posterior uveal melanoma.  Retina 1996;16(2):129-134.
  217. Harbour JW, Murray TG, Hamasaki D, Cicciarelli N, Hernandez E, Smith B, Windle J, O’Brien JM: Local carboplatin therapy in transgenic murine retinoblastoma.  Invest Ophthalmol Vis Sci 1996;37(9):1892-1898.
  218. Chang TS, Byrne SF, Gass JD, Hughes JR, Johnson RN, Murray TG: Echographic findings in benign reactive lymphoid hyperplasia of the choroid.  Arch Ophthalmol 1996;114(6):669-675.
  219. Kim JE, Flynn HW Jr, Rubsamen PE, Murray TG, Davis JL, Smiddy WE: Endophthalmitis in patients with retained lens fragments after phacoemulsification. Ophthalmology 1996;103(4):575-578.
  220. Foster RE, Martinez JA, Murray TG, Rubsamen PE, Flynn HW Jr, Forster RK: Useful visual outcomes after treatment of Bacillus cereus endophthalmitis. Ophthalmology 1996;103(3):390-397.
  221. Kangas TA, Bennett SR, Flynn HW Jr, Murray TG, Rubsamen PE, Han DP, Mieler WF, Williams DF, Abrams GW: Reversible loss of light perception after vitreoretinal surgery.  Am J Ophthalmol 1995;120(6):751-756.
  222. Steeves RA, Tompkins DT, Nash RN, Blair JR, Gentry LL, Paliwal BR, Murray TG, Mieler WF: Thermoradiotherapy of intraocular tumors in an animal model: concurrent vs. sequential brachytherapy and ferromagnetic hyperthermia.  Intl J Rad Oncol Biol Phys 1995;33(3):659-662.
  223. Harbour JW, Smiddy WE, Rubsamen PE, Murray TG, Davis JL, Flynn HW Jr: Pars plana vitrectomy for chronic pseudophakic cystoid macular edema.  Am J Ophthalmol 1995;120(3):302-307.
  224. Cohen SM, Flynn HW Jr, Murray TG, Smiddy WE: Endophthalmitis after pars plana vitrectomy. The Postvitrectomy Endophthalmitis Study Group (Review). Ophthalmology 1995;102(5):705-712.
  225. Ksander BR, Murray TG: Immunotherapy of ocular tumors using lymphokine gene transfer. J Ophthalmic Photogr 1995;17(1):36-37.
  226. Munoz M, Parrish RK, Murray TG: Open-angle glaucoma after pars plicata lensectomy and vitrectomy for congenital cataracts.  Am J Ophthalmol 1995;119(1):103-104.
  227. Murray TG: Retinoblastoma; current understanding and management. Fla Ophthalmologist 1994;15(4):8.
  228. Han DP, Nanda SK, O’Brien WJ, Guy J, Murray TG, Boldt HC: Evaluation of anterior segment tolerance to short-term intravitreal perfluoron.  Retina 1994;14(3):219-224.
  229. Han DP, Wang Q, Hartz A, Jaffe GJ, Murray TG, Boldt HC, Arrindell EL, Coe E, Abrams GW, Mieler WF: Postoperative fibrin formation and visual outcome after pars plana vitrectomy.  Retina 1994;14(3):225-230.
  230. Campochiaro PA, Lim JI, Bloome MA, Conway BP, Flynn HW Jr, Grand MG, Ibanez HE, Meredith TA, Murray TG, Myers S, Packo KH, Pheasant T, Richmond PP, Ridley M, Weiter JJ, Wilkinson CP: Aminoglycoside toxicity in the treatment of endophthalmitis. Arch Ophthalmol 1994;112:48-53.
  231. Kim JE, Flynn HW Jr, Smiddy WE, Murray TG, Rubsamen PE, Davis JL, Nicholson DH: Retained lens fragments after phacoemulsification. Ophthalmology 1994;101(11):1827-1832. Comment: 1995;102:1735-1736.
  232. Rubsamen PE, Flynn HW Jr, Civantos JM, Smiddy WE, Murray TG, Nicholson DH, Blumenkranz MS: Treatment of massive subretinal hemorrhage from complications of scleral buckling procedures.  Am J Ophthalmol 1994;118(3):299-303.
  233. Sharkey JA, Murray TG: Safety of vitrectomy instruments: implication of design. Retina 1994;14(2):188-189.
  234. Sharkey JA, Murray TG: Identification of the ora serrata and ciliary body by transillumination in eyes undergoing transscleral fixation of posterior chamber intraocular lenses. Ophthalmic Surgery 1994;25(7):479-480.
  235. Aaberg TM Jr, Flynn HW Jr, Murray TG: Intraocular ceftazidime as an alternative to the aminoglycosides in the treatment of endophthalmitis. Arch  Ophthalmol 1994;112:18-19.
  236. Irvine WD, Flynn HW Jr, Murray TG, Rubsamen PE: Retained lens fragments after phacoemulsification manifesting as marked intraocular inflammation with hypopyon. Am J Ophthalmol 1992;114(5):610-614.
  237. Boldt HC, Abrams GW, Murray TG, Han DP, Mieler WF: The lowest effective dose of tissue plasminogen activator for fibrinolysis of postvitrectomy fibrin. Retina 12(3 Suppl.):1992;S75-S79.
  238. Steeves RA, Murray TG, Moros EG, Boldt HC, Mieler WF, Paliwal BR: Concurrent ferromagnetic hyperthermia and 125I brachytherapy in a rabbit choroidal melanoma model. Intl J Hyperther 1992;8(4):443-449.
  239. Murray TG, Jaffe GJ, McKay BS, Han DP, Burke JM, Abrams GW: Collagen shield delivery of tissue plasminogen activator: functional and pharmacokinetic studies of anterior segment delivery. Refractive & Corneal Surgery 1992;8(1):44-48, discussion 1992;8(1):48-53.
  240. Murray TG, Boldt HC, Lewis H, Abrams GW, Mieler WF, Han DP: A technique for facilitated visualization and dissection of the vitreous base, pars plana, and pars plicata. Arch Ophthalmol 1991;109(10):1458-1459.
  241. Murray TG, Burton TC, Rajani C, Lewandowski MF, Burke JM, Eells JT: Methanol poisoning. A rodent model with structural and functional evidence for retinal involvement. Arch Ophthalmol 1991;109(7):1012-1016.
  242. Swift PS, Stauffer PR, Fries PD, Kaleta-Michaels S, Murray TG, Sneed PK, Phillips TL, Char DH: Microwave hyperthermia for choroidal melanoma in rabbits. Invest Ophthalmol Vis Sci 1990;31(9):1754-1760.
  243. Murray TG, Abrams GW: A new self-sealing needle for iris suture fixation. Arch Ophthalmol 1990;108(5):746-747.
  244. Murray TG, Abrams GW, Stanley J: Pars plana vitrectomy in the management of dislocated posterior chamber lenses.  Am J Ophthalmol (Letter) 1990;109(3):362.
  245. Murray TG, Stern WH, Chin DH, MacGowan-Smith EA: Collagen shield heparin delivery for prevention of postoperative fibrin.  Arch Ophthalmol 1990;108(1):104-106.
  246. Dragon DM, Robin AL, Pollack IP, Quigley HA, Green WR, Murray TG, Hotchkiss ML, D’Anna S: Neodymium: YAG laser iridotomy in the cynamologous monkey.  Invest Ophthalmol Vis Sci 1985;26(6):789-796.
  247. Joiner KA, Schmetz MA, Sanders ME, Murray TG, Hammer CH,  Dourmashkin R, Frank MM:  Multimeric complement component C9 is necessary for killing of Escherichia coli J5 by terminal attack complex C5b-9. Proc Natl Acad Sci 1985;82(14):4808-4812.
  248. Murray TG, Green WR, Maumenee IH, Kopits SE: Spondyloepiphyseal dysplasia congenita.  Light and microscopic studies of the eye. Arch Ophthalmol 1985;103:407-411.
  249. Pollack IP, Robin AL, Dragon DM, Green WR, Quigley HA, Murray TG, Hotchkiss ML: Use of Neodymium: YAG laser to create iridotomies in monkeys and humans. Trans Am Acad Ophthalmol Soc 1984;82:307-328.

Collaborative Ocular Melanoma Study: Juried or referred journal articles and exhibitions:

  1. COMS Group: I-125 Brachytherapy for Choroidal Melanoma Photographic and Angiographic Abnormalities:  The Collaborative Ocular Melanoma Study: COMS Report No. 30. Ophthalmol.  2009, Jan;116(1):106-115.
  2. COMS Group: Baseline Echographic Characteristics of Tumors in Eyes of Patients Enrolled in the Collaborative Ocular Melanoma Study: COMS Report No. 29. Ophthalmol.  2008, Aug;115(8):1390-97.
  3. COMS Group: Incidence of cataract and outcomes after cataract surgery in the first 5 years     after iodine 125 brachytherapy in the Collaborative ocular Melanoma Study: COMS Report    No. 27. Ophthalmol.  2007, Jul;114(7):1363-71.
  4. COMS Group: Quality of Life After Iodine I25 Brachytherapy vs Enucleation for Choroidal   Melanoma: 5 Year Results From the Collaborative Ocular Melanoma Study: COMS QOLS     Report No. 3. Arch Ophthalmol.  2006; 124: 226-238.
  5. COMS Group:  The COMS randomized trial of iodine 125 brachytherapy for choroidal    melanoma: V. Twelve-year mortality rates and prognostic factors:  COMS report No. 28.      Arch Ophthalmol. 2006, Dec;124(12):1684-93.
  6. COMS Group: Development of metastatic disease after enrollment in the COMS trials for       treatment of choroidal melanoma:  Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol. 2005 Dec;123(12):1639-43.
  7. COMS Group: Time trends in personnel certification and turnover in the Collaborative Ocular Melanoma Study.  Clin Trials. 2004;1(4):377-86.
  8. COMS Group:  The Collaborative Ocular Melanoma Study (COMS) randomized trial of prenucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. Am J Ophthalmol. 2004 Dec; 138(6):936-51.
  9. COMS Group:  Screening for metastasis from choroidal melanoma; the Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol. 2004 June 15;22(12):2438-44.
  10. COMS Group: Ten-Year Follow-up of Fellow Eyes of Patients Enrolled in Collaborative Ocular Melanoma Study Randomized Trials.  COMS report number 22. Ophthalmol.  2004, May;111(5):966-76.
  11. COMS Group: Mortality after deferral of treatment or no treatment for choroidal melanoma.  Am J Ophthalmol. 2003 Jul;136(1):47-54.
  12. COMS Group: Comparison of clinical, echographic, and histopathological measurements from eyes with medium-sized choroidal melanoma in the Collaborative Ocular Melanoma study. COMS Report No. 21.  Arch Ophthalmol 2003;121:1163-1171.
  13. COMS Group: Trends in size and treatment of recently diagnosed choroidal melanoma, 1987-1997.  Findings from patients examined at COMS centers: COMS Report No. 20. Arch Ophthalmol 2003;121:1156-1162.
  14. COMS Group: Development and validation of disease-specific measures for choroidal melanoma: COMS-QOLS Report No. 2. Arch Ophthalmol 2003; 121:1010-1020.
  15. COMS Group: The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. IV. Local treatment failure and enucleation in the first 5 years after brachytherapy; COMS Report No. 19. Ophthalmology 2002; 109:2197-2206.
  16. COMS Group: Sociodemographic and clinical predictors of participation in two randomized trials:  findings from the Collaborative Ocular Melanoma Study COMS report no. 7. Control Clin Trials. 2001 Oct; 22(5):526-37.
  17. COMS Group: The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: Report No. 18. Arch Ophthalmol 2001; 119:969-982.
  18. COMS Group: The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, II: Report No. 17. Arch Ophthalmol 2001; 119:951-965.
  19. COMS Group: The COMS randomized Trial of I-125 Brachytherapy for Medium Choroidal Melanoma. I. Visual Acuity after 3 years. Report No. 16, Part 1. Ophthalmol 2001;108:348-366.
  20. COMS Group: Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS):  COMS Report No. 15. Arch Ophthalmol 2001 May; 119(5):670-6.
  21. COMS Group: Absence of type I estrogen receptors in choroidal melanoma: analysis of Collaborative Ocular Melanoma Study (COMS) eyes. Am J Ophthalmol. 2001 June; 131(6):788-91.
  22. COMS Group: Cause-specific mortality coding. methods in the collaborative ocular melanoma study.  COMS Report No. 14. Control Clin Trials. 2001 Jun; 22(3):248-62.
  23. COMS Group: Echography (ultrasound) procedures for the Collaborative Ocular Melanoma Study Group (COMS), Report No. 12, Part 1. July/August 1999.
  24. COMS Group: Quality of life assessment in the collaborative ocular melanoma study:  design and methods.  (COMS-QOLS) Report No. 1.  COMS Quality of Life Study Group. Ophthalmol Epidemiol. 1999 Mar; 6(1):5-17.
  25. COMS Group: The COMS randomized Trial of Pre-Enucleation Radiation of Large Choroidal Melanoma. III: Local complications and observations following enucleation. COMS Report No. 11. Am J Ophthalmol 1998; 126:362-372.
  26. COMS Group: The COMS randomized Trial of Pre-Enucleation Radiation of Large Choroidal Melanoma. II: Initial Mortality Findings. COMS Report No. 10. Am J Ophthalmol 1998; 125:779-796.
  27. COMS Group: The COMS randomized Trial of Pre-enucleation Radiation of Large Choroidal Melanoma.  I: Characteristics of Patients Enrolled and Not Enrolled.  COMS Report No. 9. Am J Ophthalmol 1998; 125:767-778.
  28. COMS Group: Histopathologic Characteristics of Uveal Melanomas in Eyes Enucleated from the Collaborative Ocular Melanoma Study. COMS Report No. 6. Am J Ophthalmol 1998; 125:745-766.
  29. COMS Group: Factors predictive of growth and treatment of small choroidal melanoma. COMS Report No. 5. Arch Ophthalmol 1997;115:1537-1544.
  30. COMS Group: Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. Ophthalmic Surgery & Lasers, 1997;28(3):185-194.
  31. COMS Group: Mortality in Patients with small Choroidal Melanoma. COMS Report No. 4. Arch Ophthalmol 1997;115:886-893.
  32. COMS Group: Posterior uveal melanoma management: Collaborative Ocular Melanoma Study (COMS).  Fla Ophthalmologist 1995;17(3):9-11.
  33. COMS Group: Correlation of transillumination size and microscopic measurement of choroidal melanoma.  Invest Ophthalmol Vis Sci 1994;35(4):1925.
  34. COMS Group: Histopathologic review of 1,901 uveal melanomas. Invest Ophthalmol Vis Sci 1994;35(4):1925.
  35. COMS Group: Evaluation of radiation retinopathy with color photography alone vs. color photography fluorescein angiography.  Invest Ophthalmol Vis Sci 1994;35(4):1722.
  36. COMS Group: Design and methods of a clinical trial for a rare condition: The Collaborative Ocular Melanoma Study, COMS Report No. 3. Controlled Clin Trials 1993;14:362-391.
  37. COMS Group: Complications of enucleation surgery. COMS Report 2. Franklin RM, ed.: Proceedings of the Symposium on Retina and Vitreous. Kugler Publications, New York, 1993;181-190.
  38. COMS Group: Factors predictive of choice of treatment among patients with choroidal melanoma. Invest Ophthalmol Vis Sci 1993;34(4):967.
  39. COMS Group: Phantom or real?  Verification of nonrandomized patients evaluated for randomized clinical trials of a rare disease. Controlled Clin Trials 1993;14(5):441.
  40. COMS Group:  Five-year progress report from the Collaborative Ocular Melanoma Study. Invest Ophthalmol Vis Sci 1992;33(4):1254.
  41. COMS Group: Socio-demographic factors of patient participation in randomized trials: Findings from the COMS. Invest Ophthalmol Vis Sci 1991;32(4):980.
  42. COMS Group: Sociodemographic characteristics associated with patient enrollment in the Collaborative Ocular Melanoma Study. Controlled Clinical Trials 1991;12(5):657.
  43. COMS Group: Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study Report No. 1. Arch Ophthalmol 1990;108:1268-1273.
  44. COMS Group: Is standardization possible in a multicenter clinical trial in which 45 medical centers and 500 clinical professionals are involved? The COMS experience. Controlled Clin Trials 1990;11(4):275.
  45. COMS Group: Non-ocular cancers in patients with choroidal melanoma. Ophthalmol 1990;97 (7):837-838.

Published Abstracts:

  1. Houston SK, Murray TG, Decatur CL, Pina Y, Cavalcante L, Lampidis T. Use of 2-fluorodeoxy-d-glucose (2-FDG) to Target the Chemoresistant, Hypoxic Cell Population in Advanced LHBetaTAg Retinal Tumors. [ARVO Abstract].  2487/D780, 2011.
  2. Murray TG, Decatur C, Pina Y, Houston S, Cavalcante L, Lampidis T.A Novel, Oral, Non-invasive Method of Delivery For The Glycolytic Inhibitor 2-deoxy-d-glucose in the Treatment of Retinoblastoma. [ARVO Abstract]. 1592, 2011.
  3. Decatur C, Pina Y, Houston S, Cavalcante L, Murray TG, Lampidis T. Evaluating the Glycolytic Pathway in Retinoblastoma:  A Molecular Mechanistic Approach Using the Glycolytic  Inhibitor 2-deoxy-D-glucose in vitro and in vivo. [ARVO Abstract]. 2483/D776, 2011.
  4. Pina Y, Decatur C, Houston S, Cavalcante L, Lampidis T, Murray TG. Mammalian Target of Rapamycin In Combination With Chemotherapy: Upstream Regulation of Anaerobic Glycolysis to Target the Chemoresistant Cell Population in Retinoblastoma. [ARVO Abstract]. 2484/D777.
  5. Ksander BR, Bosch JJ, Frank NY, Ostrand-Rosenberg S, Murray TG, Frank MH, Kolovou PE: T Cells Targeting Cancer Stem Cells in Uveal Melanoma. [ARVO Abstract].  842/D1054, 2010.
  6. Pina Y, Houston S, Scott W, Nathanson L, Schefler A, Lampidis T, Celdran M, Hernandez E, Murray TG:  Retinoblastoma Molecular Genomics:  Regional Differences in the Molecular Genomics Expression Following Treatment With 2-Deoxy-D-Glucose in LHBETATAG Retinal Tumors. [ARVO Abstract]. 1576, 2010
  7. Mutapcic L, Murray TG, Aziz-Sultan MA, Schefler AC, Quintero Wolfe S, Hess DJ, Fernandes CE, Dubovy SR:  Supraselective Intra-Ophthalmic Artery Chemotherapy: Evaluation of Treatment Related Complications in Advanced Retinoblastoma.  [ARVO Abstract]. 1579, 2010.
  8. Houston SK, Pina Y, Scott WK, Nathanson L, Schefler AC, Murray TG:  Regional and Temporal Differences in the Genetic Expression of LHBETATAG Retinoblastoma Tumors. [ARVO Abstract]. 2066/A6, 2010. 
  9. Murray TG, Pina Y, Houston S, Hernandez E, Celdran M, Feuer W, Lampidis T: Retinoblastoma Tumor Burden Control: Periocular m-TOR Inhbitior Rapamycin Decreases Tumor Burden in Advanced LHBETATAG Murine Retinoblastoma. [ARVO Abstract]. 2067/A7, 2010.
  10. Suk KK, Lalwani GA, Murray TG, Hess D, Berrocal AM: Retinal Findings in Patients With Aicardi Syndrome.   [ARVO Abstract]. 2209/A308, 2010.
  11. Williams BK,  Schefler AC, Garonzik SN, Shi W, Gologorsky D, Feuer WJ, Murray TG:  Orbital Disease and Surgery. [ARVO Abstract]. 3528/A33, 2010.
  12. Berrocal AM, Houston SK, Pina Y, Bascom Palmer Imaging Group, Murray TG: Intraoperative Spectral Domain Optical Coherence Tomography (SD-OCT) Imaging of Complex Pediatric Retinal Disease.  [ARVO Abstract]. 3861, 2010.
  13. Khan S, Finger PT, Sankull P, Seregard S, Gologorsky D, Murray T, Kivela T, Eskelin S, Raut R, Corriveau C:  Clinical and Pathologic Characteristics of Biopsy Proven Iris Melanomas:  Results of a Multicenter International Study.  [ARVO Abstract]. 3808, 2010.
  14. Kolovou EP, Frank NY, Giani A, Murray TG, Frank MH, Ksander BR:  ABCB5: a Novel Cancer Stem Cell Marker in Retinoblastoma. [ARVO Abstract]. 4764, 2010.
  15. Parke DW, Murray TG, Flynn HW:  Open Globe Injuries: Computerized Tomography and Echography in Clinical Management.  [ARVO Abstract]. 6026/A334, 2010.
  16. Murray TG, Pina Y, Boutrid H, Cebulla CC, Jockovich ME: Role of Matrix Metalloproeinase-9 in LH BETA Tag Retinal tumor Growth. [ARVO Abstract]. 2039, 2009.
  17. Cebulla CM, Ruggeri M, Murray TG, Hernandez E: Optical Coherence Tomography in a Murine Retinal Detachment Model. [ARVO Abstract].  3798/A358, 2009.
  18. Alegret AM, Schefler AC, Pina Y, Boutrid H, Hernandez E, Ruggeri M, Jiao S, Murray TG: Recent Advancements in 532 Green Laser Technology and Probe Enhancement: Clinical Assessment and Laboratory Evaluation.  [ARVO Abstract].  2082, 2009
  19. Pina Y, Boutrid H, Cebulla CC, Schefler AC, Alegret A, Jager MJ, Ly LV, Jockovich ME, Murray TG: Retinoblastoma Tumor Burden: Effect of Macrophage Depletion on LHBETATAG Retinal Tumor Growth. [ARVO Abstract]. 2038, 2009
  20. Boutrid H, Pina Y, Jockovich ME, Cebulla CC, Lampidis TJ, Murray TG: Vascular Targeting Agent and Glycolytic Inhibitor Combination Therapy Decreases Tumor Burden in Advanced LHBETATAG Murine Retinoblastoma. [ARVO Abstract]. 2043, 2009.
  21. Fernandes CE, Schefler AC, Reichbach J, Podda A, Davis JA, Alvarez OA, Barredo JC, Lewis N, White E, Murray TG:  Chemotherapy Plus Cyclosporine A for the Treatment of Intraocular Retinoblastoma. [ARVO Abstract]. 1692/A, 2009
  22. Williams SL, Berrocal AM, Hess DJ, Shi W, Murray TG: Fundus Pigmentation in Treatment-requiring Retinopathy of Prematurity (ROP).  [ARVO Abstract]. 3157/A504, 2009
  23. Parrott M, Flynn Jr HW, Wykoff CC, Miller D, Murray TG, Smiddy WE, Davis JL: Nosocomial Acute-Onset Postoperative Endophthalmitis at a University Teaching Hospital (1995-2008)  [ARVO Abstract] 3557/D1070, 2009
  24. Alliman K, Flynn Jr HW, Lalwani G, Quinn C, Davis JL, Murray TG, Rosenfeld P, Smiddy WE: Acute-Onset Endophthalmitis Following Clear Corneal Cataract Surgery: A 12-Year Review (1996-2008) [ARVO Abstract] 3564/D1077, 2009
  25. Pina Y, Boutrid H, Jockovich ME, Murray TG: Spatial Configuration of Neovasculature in Retinoblastoma: A Proposed Model for Tumor Vascular Development.  [ARVO Abstract] 18/A6, 2008
  26. Boutrid H, Jockovich ME, Cebulla C, Lampidis TJ, Murray TG: Vascular Targeting Agent and Cytotoxic Chemotherapy Increase Hypoxia in LHBETATAG Murine Retinoblastoma.  [ARVO Abstract] 21/A9, 2008
  27. Murray TG, Boutrid H,  Hernandez E, Shi W, Feuer WJ, Jockovich ME: Antiangiogenic Therapy for Retinoblastoma: Effect of Tumor Burden and Dose Schedule in the Murine LH BETATAG Transgenic Model.  [ARVO Abstract] 22/A10, 2008
  28. Cebulla CM, Jockovich ME, Boutrid H, Piña Y,  Ruggeri M, Jiao S, Bhattacharya SK, Feuer WJ, Murray TG: Effect of SU1498, an Inhibitor of Vascular Endothelial Growth Factor Receptor-2, in a Transgenic Murine Model of Retinoblastoma.  [ARVO Abstract] 23/A11, 2008
  29. Lalwani GA, Schefler AC, Feuer WJ, Davis II RP, Murray TG: Bevacizumab for Radiation Retinopathy After Iodine-125 Plaque Brachytherapy for Posterior Uveal Malignant Melanoma. [ARVO Abstract], 49/A37, 2008
  30. Alegret M, Jockovich ME, Pina Y, Boutrid H, Hernandez E, Murray TG: Tumor Infiltrating Lymphocytes in Retinal Tumors From LHBETATAG mice.  [ARVO Abstract], 75/A63, 2008
  31. Jockovich ME, Pina Y, Boutrid H, Murray TG: Bone Marrow Derived Macrophages Are Present in Retinal Tumors from LHBETATAG Mice.  [ARVO Abstract], 76/A64, 2008
  32. Bokhoor PI, Miller D, Schefler AC, Murray TG: Epidemiology and Microbiology of Pediatric Socket/Orbital Implant Infections Following Enucleation Secondary to Retinoblastoma. [ARVO Abstract], 1442/D676, 2008
  33. Moshfeghi AA, Flynn Jr HW, Murray TG, Rosenfeld PJ, Gaitan J, Lalwani GA, Lujan B, Gallogly P: Endophthalmitis Following Intravitreal Injections Is Very Rare in the Anti-VEGF Era.  [ARVO Abstract], 2867, 2008
  34. Pina Y, Cebulla CM, Murray TG, Alegret A, Dubovy S, Boutrid H, Feuer W, Jockovich ME:  Blood Vessel Maturation in Human Uveal Melanoma: Spatial Configuration of Endothelial Vessel Maturation and Neovasculature and Its Impact on Ocular Treatment. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 48: Abstract nr E- 4780, 2007
  35. Bosch JJ, Iheagwara UK, Murray TG, Lotem M, Ksander BR, Ostrand-Rosenberg S. Uveal Melanoma Cell-Based Vaccines Activate CD4+ T Lymphocytes That Cross-React With Primary and Metastatic Uveal Melanoma Cells. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 48: Abstract nr E- 1945, 2007
  36. Flynn HW Jr., Gregori NZ, Miller D, Scott IU, Davis JL, Murray TG. Candida Endophthalmitis Following Cataract Surgery: Management Strategies, and Visual Acuity Outcomes. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 48: Abstract nr E- 679, 2007
  37. Davis R II, Cebulla CM, Ehlies FJ, Murray TG. Echographic Localization of Periocular Carboplatin in Advanced Retinoblastoma. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 48: Abstract nr E- 5250, 2007
  38. Cebulla CM, Jockovich ME, Pina Y, Alegret A, Boutrid H, Hackam A, Feuer W, Murray TG. Basic Fibroblast Growth Factor Expression in Retinoblastoma Progression and Survival [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 48: Abstract nr E- 3987, 2007.
  39. Murray TG, Cebulla CM, Alegret A, Pina Y, Boutrid H, Jockovich ME. Targeting the Tumor Microenvironment as a Therapeutic Strategy for Retinoblastoma [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 48: Abstract nr E- 1585, 2007
  40. Jockovich ME, Diaz-Caneja J, Pina Y, Boutrid H, Cebulla CM, Murray. Role of Tumor Associated Macrophages in Retinoblastoma Tumor Growth. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 48: Abstract nr E- 1587, 2007
  41. Jiao S, Ruggeri M, Wehbe H, Gregory G, Jockovich ME, Puliafito CA, Murray TG. Quantitative Imaging of Eye Tumor in the Mouse Model of Retinoblastoma With Spectral-Domain Optical Coherence Tomography. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 48: Abstract nr E- 1588, 2007
  42. Yi H, Tell S, Jockovich ME, Murray TG, Hackam AS. The Wnt Signaling Pathway Has Tumor Suppressor Properties in Retinoblastoma. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 48: Abstract nr E- 1593, 2007
  43. Alegret AM, Pina Y, Murray TG, Suarez F, Hayden B, Cebulla CM, Feuer W, Boutrid H, Jockovich ME. Differential Induction of Apoptosis in the Treatment of LHBETATAG Retinoblastoma Following Vessel Targeting. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 48: Abstract nr E- 1600, 2007
  44. Boutrid H, Cebulla CM, Pina Y, Jockovich ME, Lampidis TJ, and Murray TG. Regional Hypoxia in LHBetaTag Murine Retinoblastoma: Implication for Novel Treatments. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 48: Abstract nr E- 1601, 2007
  45. Cebulla CM, Jockovich ME, Bajenaru L, Murray TG. Gelatinase Activity in Human Retinoblastoma and Choroidal Melanoma. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 47: Abstract nr E- 2805, 2006
  46. Tell S, Yi H, Jockovich ME, Murray TG, Hackam AS. The Canonical Wnt Signaling Pathway Regulates the Viability of Retinoblastoma Tumor Cells. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 47: Abstract nr E- 2806, 2006
  47. Schiedler V, Murray TG, Dubovy SR. Snare Technique For Enucleation Of Eyes With Advanced Retinoblastoma. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 47: Abstract nr E- 2812, 2006
  48. Jockovich ME, Pina Y, Suarez F, Hernandez E, Murray TG. Blood Vessel Heterogeneity in Retinal Tumors From LHBETATAG Mice Limits Vessel Targeting Therapy. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 47: Abstract nr E- 2833, 2006
  49. Miller JJ, Flynn HW Jr., Smiddy WE, Murray TG, Scott IU, Miller D. Endophthalmitis Caused by Bacillus. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 47: Abstract nr E- 5279, 2006.
  50. Major JC Jr., Flynn HW Jr., Miller D, Smiddy WE, Murray TG. Antibiotic Sensitivities and Visual Acuity Outcomes in Endophthalmitis Caused by Methacillin–Sensitive (MSSA) versus Methacillin–Resistant (MRSA) Staphylococcus aureus. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 47: Abstract nr E- 5282, 2006
  51. Flynn HW Jr., Miller JJ, Scott IU, Smiddy WE, Murray TG, Miller D. Acute–Onset Endophthalmitis Following Cataract Surgery in a University Teaching Hospital (2000–2005). [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 47: Abstract nr E- 5293, 2006
  52. Hartley KL, Smiddy WE, Flynn HW Jr., Murray TG, Voo I, Venkatraman AS. Pars Plana Vitrectomy With Internal Limiting Membrane Peeling For Diabetic Macular Edema. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 47: Abstract nr E- 3866, 2007
  53. Hayden BC, Schefler AC, Abramson DH, Murray TG, and Echography Study Group. Echographic Features of Melanocytoma Detected by Standard and High–Resolution Ultrasound. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 47: Abstract nr E- 2260, 2006
  54. Murray TG, Jockovich ME, Suarez F, Hernandez E, Feuer W. Combined Angiostatic and Periocular Chemotherapy Using Combretastatin A4P and Carboplatin in the Treatment of LHBETATAG Transgenic Murine Model of Retinoblastoma. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 47: Abstract nr E- 2290, 2006
  55. Suarez F, Jockovich ME, Hernandez E, Parel JM, Murray TG. Taxol in the Treatment of Retinal Tumors of LH BETATAG Murine Transgenic Model of Retinoblastoma. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 47: Abstract nr E- 2801, 2006
  56. Bosch JJ, Thompson JA, Dissanayake SK, Murray TG, Ksander BR, Ostrand–Rosenberg S. Primary and Metastatic Uveal Melanoma Cells Genetically Modified to Express HLA–DR and CD80 Present Class II Restricted Tumor Antigens and Activate Tumor–Specific CD4+ T Cells. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 47: Abstract nr E- 5165, 2006
  57. Miller DM, Flynn HW Jr., Miller D, Scott IU, Smiddy WE, Murray TG, Venkatraman AS. Endophthalmitis Caused by Staphylococcus epidermidis: Clinical Outcomes and in vitro Antibiotic Susceptibilities. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 46: Abstract nr E- 3295, 2005
  58. Jockovich ME, Moshfeghi AA, Hernandez E, Clifford PD, Murray TG. Posterior Juxtascleral Injection of Anecortave Acetate: Localization in Rabbit Eyes by Magnetic Resonance and Ecographic Imaging. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 46: Abstract nr E- 482, 2005
  59. Flynn HW, Moshfeghi AA, Davis JL, Kitchens JW, Murray TG, Puliafito CA, Rosenfeld PJ, Scott IU,  Smiddy. Non–infectious Pseudohypopyon Following Intravitreal Triamcinolone Acetonide (IVTA) Injection. [ARVO Abstract] Invest. Ophthalmol. Vis. Sc 46: Abstract nr E- 486, 2005
  60. Cebulla CM, Jockovich ME, Murray TG. Anecortave Acetate Modulates MMP–2, MMP–9 and Vegf Receptor Expression in the LHßTAG Mouse Model of Retinoblastoma. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 46: Abstract nr E- 1106, 2005
  61. Schefler AC, Cicciarelli N, Murray TG. Macular Retinoblastoma: Evaluation of Tumor Control, Local Complications, and Visual Outcomes for Eyes Treated With Aggressive Chemotherapy and Laser Ablation. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 46: Abstract nr E- 1110, 2005
  62. Murray TG, Toledano S, Markoe A, Schefler AC. Failure Analysis for Globe Conservation in Advanced Intraocular Retinoblastoma. [ARVO Abstract] Invest. Ophthalmol. Vis. Sc 46: Abstract nr E- 1111, 2005
  63. Gallogly P, Moore J, Scott IU, Flynn HW Jr, Smiddy WE, Murray TG, Feuer W. Retained Lens Fragment in the New Millenium. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 46: E- 5511, 2005
  64. Quinn CD, Flynn HF Jr, Gedde SJ, Budenz DL, Scott IU, Palmberg PF, Smiddy WE, Murray TG, Parrish RK II, Fantes FE. Delayed–onset Bleb–Associated Endophthalmitis: Clinical Features and Visual Acuity Outcomes. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 46: Abstract nr E- 5552, 2005
  65. Couvillion SS, Flynn HW Jr, Murray TG, Ehlies FJ, Miller D, Smiddy WE. Correlation of Echographic Findings With Outcomes in Patients With Endophthalmitis. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 46: Abstract nr E- 5568, 2005
  66. Murray TG. Combined Anti–angiogenic and Peri–ocular Chemotherapy utilizing Anecortave Acetate and Carboplatin in the Treatment of Retinal Tumors in the LHBETATAG Murine Transgenic Model of Retinoblastoma. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 45: Abstract nr E- 3362, 2004
  67. Berrocal AM, Mavrofrides EC, Murray TG, Hess D, Johnson R. Retinopathy of prematurity (ROP)screening and treatment experience at Jackson Memorial Hospital/Bascom Palmer Eye Institute 2002–2003. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 45: Abstract nr E- 4043, 2004
  68. Garonzik SN, Margolis R, Murray TG. Ocular Prosthetic Management: Evaluation of prospective, serial custom prosthetic refitting on improved socket anatomy, function and cosmesis. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 45: Abstract nr E- 4704, 2004
  69. Lee JE, Mavrofrides EC, Smiddy WE, Scott IU, Rosenfeld PJ, Flynn HW Jr, Murray TG, Berrocal AM, Puliafito CA. Intravitreal triamcinolone for the treatment of macular edema from central retinal vein occlusion. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 45: Abstract nr E- 5238, 2004
  70. Peracha MO, Benz MS, Mieler WF, Holz ER, Murray TG, Couvillion SS. Visual Outcomes following Pars Plan Vitrectomy for Complications of Radiation Retinopathy. [ARVO Abstract] Invest. Ophthalmol. Vis. Sc 45: Abstract nr E- 1996, 2004
  71. Smiddy RJ, Smiddy WE, Ba’ath B, Flynn HW Jr, Murray TG, Feuer W. Endophthalmitis: Are Subconjunctival Antibiotics Necessary? [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 45: Abstract nr E- 524, 2004
  72. Rosenberg KD, Murray TG, Berrocal A, Ysasaga E, Loo R, Aragon A, Douglas M, Feuer W, Gregori G. Continuous versus Non-continuous Laser Photocoagulation for the Treatment of Threshold Retinopathy of Prematurity. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 44: Abstract nr E- 596, 2003
  73. Murray TG, Escalona-Benz E, Hayden BC, Cicciarelli N, Hernandez E, Windle JJ. Subconjunctival Anecortave Acetate, an Angiostatic Steroid, in the Treatment of a Murine Model of Retinoblastoma. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 44: Abstract nr E- 934, 2003
  74. Moore JK, Scott IU, Flynn HW Jr., Smiddy WE, Murray TG, Pereira MB, Jorge R. Cystoid Macular Edema in Eyes Undergoing Pars Plana Vitrectomy for Retained Lens Fragments. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 44: Abstract nr E- 3110, 2003
  75. Escalona-Benz E, Murray TG, Benz MS, Villate N, Hayden BC. Correlation between Optos Ultra Widefield Digital Imaging, Standardized Fundus Photography, and B-Scan Echography in the Detection of Posterior Segment Tumors. [ARVO Abstract] Invest. Ophthalmol. Vis. Sc 44: Abstract nr E- 3644, 2003
  76. Dubovy SR, Colomine C, Jampol LM, Murray TG. FNAB in the Evaluation of Atypical Uveal Effusion Syndrome: Histopathological Review. [ARVO Abstract] Invest. Ophthalmol. Vis. Sc 44: Abstract nr E- 1591, 2003
  77. Benz MS, Escalona-Benz EM, Murray TG, Eifrig CW, Yoder DM, Moore JK, Cruz-Villegas V. Immediate Postoperative Use of a Single Topical Agent to Prevent Intraocular Pressure Elevation after Pars Plana Vitrectomy with Long-acting Gas Tamponade. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 44: Abstract nr E- 3014, 2003
  78. Moore JK, Scott IU, Flynn HW Jr., Murray TG, Smiddy WE, Jorge R, Pereira MB, Kim JE, and Vilar NF. Retinal Detachment in Eyes Undergoing Pars Plana Vitrectomy for Removal of Retained Lens Fragments. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 43: Abstract nr E- 633, 2002
  79. Escalona-Caamano EM, Murray TG, Benz MS, Hayden BC, Garonzik S, Hernandez E.  Magnetically Integrated Microporous Implant: Safety and Efficacy of Secondary Stainless Steel Posting Following Enucleation Surgery. [ARVO Abstract] Invest. Ophthalmol. Vis. Sc 43: Abstract nr E- 3048, 2002
  80. Flynn HW Jr., Scott IU, Murray TG, Feuer WJ, Schiffman J. Outcomes of Surgery for Retinal Detachment Associated with Proliferative Vitreoretinopathy Using Perfluoro-n-octane: A Multicenter Study. [ARVO Abstract] Invest. Ophthalmol. Vis. Sc 43: Abstract nr E- 4504, 2002
  81. Gaitan JR, Hayden BC, Murray TG, Escalona EM, Cicciarelli N, Feuer W. Cellular Viability in Choroidal Melanoma Following Brachytherapy with Subsequent Enucleation. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 43: Abstract nr E- 1132, 2002
  82. Bosch JJ, Chen PW, Mensink HW, Jager MJ, Murray TG, Ksander BR. Microarray Analysis of Differential Gene Expression in Autologous Primary and Metastatic Uveal Melanoma. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 43: Abstract nr E- 1860, 2002
  83. Sussman DA, Escalona EM, Benz MS, Hess D, Feuer W, Ciciarelli N, Markoe A, Toledano S, Murray TG. Globe Conserving Therapy in Retinoblastoma: Comparison of Time Course of Tumor Reduction for Primary Chemoreduction Versus External Beam Radiotherapy. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 43: Abstract nr E- 2590, 2002
  84. Hayden BC, Murray TG, Gaitan JR, Raja D, Escalona EM, Hernandez E, Cicciarelli N, Windle JJ. Time Course Dependent Apoptosis Following Subconjunctival Carboplatin Therapy in the Treatment of Murine Transgenic Retinoblastoma. [ARVO Abstract]. Invest. Ophthalmol. Vis. Sc 43: Abstract nr E- 2593, 2002
  85. Murray TG, Escalona EM, Hayden BC, Cicciarelli N, Hernandez E, Feuer W, Windle JJ. Combretastatin A4 Prodrug: Subconjunctival delivery of an angiogenesis Inhibitor in the Treatment of a Murine Model of Retinoblastoma.[ARVO Abstract]. Invest. Ophthalmol Vis. Sc 43: Abstract nr E-3917, 2002
  86. Hayden, BC, Murray, TG, Hernandez, E, Cicciarrelli, N, Fulton, L, O’Brien, JM.  Differential Induction of Apoptosis in the Treatment of Murine Transgenic Retinoblastoma.[ARVO Abstract]. Invest Ophthalmol and Vis Sc 42(4):Abstract nr 2728, 2001
  87. Murray, TG, Hayden, BC, Cicciarelli, N, Scott, IU, Hernandez, E, Wu, X, Markoe, AM, Feuer, W, Fulton, L, O’Brien, JM. External Beam Radiation “Salvage” Therapy in the Treatment of Murine Transgenic Retinoblastoma  .[ARVO Abstract]. Invest Ophthalmol and Vis Sc 42(4):Abstract nr 1786, 2001
  88. Voigt M, Hayden, BC, Murray, TG, Milne P, Hamasaki D, Parel, JM. Carboplatin Coulomb Controlled Iontophoresis (CCI): Evaluation of ERG and Histopathology  [ARVO Abstract]. Invest Ophthalmol and Vis Sc 42(4):Abstract nr 1791, 2001
  89. Cicciarelli N, Murray TG, Hayden BC, Hernandez E, Milne P, Feuer W, Parel JM.Pharmacokinetics of subconjunctivally administered cyclosporine A: Local Delivery Prior to Chemotherapy for Retinoblastoma  [ARVO Abstract]. Invest Ophthalmol and Vis Sc 42(4): Abstract nr 1792, 2001
  90. Hayden, BC, Murray TG, Scott IU, Cicciarelli N, Hernandez E, Feuer W, Fulton L, O’Brien JM: Subconjunctival carboplatin in retinoblastoma: Impact of tumor burden and dose schedule. Arch Ophthalmol 2000;118 (11):1549-1554
  91. Murray TG, Cicciarelli N, Croft BC, Garonzik S, Voigt M, Hernandez E.  Magnetically integrated microporous implant: Evaluation of feasibility and efficacy. Arch Ophthalmol 2000; 118 (9):1157-1320
  92. Hayden BC, Voigt M, Murray TG, Hernandez E, Parel JM, Feuer W, Fulton L, O’Brien JM: Iontophoretic Delivery of Carboplatin in the Treatment of Murine Transgenic Retinoblastoma [ARVO Abstract]. Invest Ophthalmol and Vis Sci 41(4):S788. Abstract nr 4178, 2000
  93. Murray TG, Hayden BC, Voigt M, Milne PJ, Cicciarelli N, Hernandez E, Scott IU, Feuer W, Steele B, Parel JM: An in vivo comparison of systemic versus focal chemotherapy in the management of retinoblastoma [ARVO Abstract]. Invest Ophthalmol Vis Sci 41(4):S953. Abstract 5065, 2000
  94. Cicciarelli N, Murray TG, Hayden BC, Hernandez E, Wu X, Markoe AM, Feuer W, Fulton L, O’Brien JM: A Comparison of radiation hyperfraction in the management of murine transgenic retinoblastoma [ARVO Abstract]. Invest Ophthalmol Vis Sci 41(4):S788. Abstract nr4176, 2000
  95. Croft BH, Murray TG, Cicciarelli N, Hernandez E, Fulton L, O’Brien JM.  Efficacy of Locally Delivered Carboplatin as a function of tumor burden and cycle number in murine transgenic retinoblastoma. [Paper] IX International Congress of Ocular Oncology 1999.
  96. Murray TG, Voigt M, Croft BH, Chapon P, Parel J-M, Hernendez E: Iontophoretic delivery of carboplatin: Evaluation of pharmacokinetics and efficacy [ARVO Abstract]. Invest Ophthalmol Vis Sci 40(4):S576. Abstract nr3034, 1999
  97. Croft BH, Murray TG, Cicciarelli N, Fulton L, O’Brien JM: In vitro efficacy of combined carboplatin, etoposide, and/or vincristine with and without hyperthermia in transgenic murine retinoblastoma [ARVO Abstract]. Invest Ophthalmol Vis Sci 40(4):S577. Abstract nr3035, 1999
  98. Hughes R, Tabandeh H, Chaudhry NA, Murray TG: Intraoperative echographic localization of iodine 125 episcleral plaques for choroidal melanoma. Invest Ophthalmol Vis Sci 1999:40(4)(Suppl):956.
  99. Belfort A, Chaudhry NA, Flynn HW Jr, Murray TG: Combined cataract extraction, intraocular lens implantation and pars plana vitrectomy for localized recurrent retinal detachment and cataract. Invest Ophthalmol Vis Sci 1999:40(4)(Suppl):946.
  100. Chaudhry NA, Belfort A, Flynn HW Jr, Tabandeh H, Smiddy WE, Murray TG: Combined lensectomy, vitrectomy and scleral fixation of intraocular lens implant after closed-globe injury. Ophthalmic Surg & Lasers 1999;30:375-381.
  101. Alexandrakis G, Chaudhry NA, Flynn HW Jr, Murray TG: Combined cataract surgery, intraocular lens insertion, and vitrectomy in eyes with idiopathic epiretinal membrane. Ophthalmic Surg Lasers 1999;30:327-328.
  102. Alexandrakis G, Scott IU, Flynn HW Jr, Feuer W, Murray TG: Visual outcomes after surgery for persistent fetal vasculature (Persistent hyperplastic primary vitreous). Invest Ophthalmol Vis Sci 1999:40(4)(Suppl):945.
  103. Cicciarelli N, Murray TG, Croft BH, Voight M, Garonzik S, Hernandez E: Magnetically integrated microporous implant: Evaluation of feasibility and efficacy. Invest Ophthalmol Vis Sci 1999:40(4)(Suppl):856.
  104. Chaudhry NA, Flynn HW Jr, Tabandeh H, Mello MO, Miller D Jr, Murray TG: Ciprofloxacin-resistant pseudomonas aeruginosa at a major ophthalmic center. Invest Ophthalmol Vis Sci 1999:40(4)(Suppl):689.
  105. Ksander BR, Murray TG, Verbik D, Chen PW: Immune induced activation of genes that regulate cellular differentiation – A novel effector T cell mechanism. Invest Ophthalmol Vis Sci 1999:40(4)(Suppl):591.
  106. Croft BH, Murray TG, Cicciarelli N, Fulton L, O’Brien JM: In vitro efficacy of combined carboplatin, etoposide, and/or vincristine with and without hyperthermia in transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci 1999:40(4)(Suppl):577.
  107. Murray TG,  Voigt M, Croft BH, Chapon P, Parel JM, Hernandez E: Iontophoretic delivery of carboplatin: Evaluation of pharmacokinetics and efficacy. Invest Ophthalmol Vis Sci 1999:40(4) (Suppl):576.
  108. Cordahi GJ, Alexandrakis G, Scott IU, Murray TG: 22mm radioactive 125 iodine plaques for the management of uveal malignant melanoma. Invest Ophthalmol Vis Sci 1999:40(4)(Suppl):243.
  109. Cicciarelli N, Hamasaki D, Murray TG, Carney B, Hernandez E, O’Brien JM: Determination of functional and histologic parameters for toxicity associated with subconjunctival carboplatin. Invest Ophthalmol Vis Sci 1998:39(4)(Suppl):814.
  110. Carney B, Murray TG, Cicciarelli N, Mueller R, Hernandez E, Feuer W, O’Brien JM: Efficacy of subconjunctival carboplatin determined by tumor burden and dose schedule in murine retinoblastoma. Invest Ophthalmol Vis Sci 1998:39(4)(Suppl):814.
  111. Murray, TG, Carney B, Mueller R, Hernandez E, Feuer W, Nose I, Parel JM, O’Brien JM: Subconjunctival carboplatin and FM hyperthermia in murine transgenic retinoblastoma therapy. Invest Ophthalmol Vis Sci 1998:39(4)(Suppl):814.
  112. Verbik DJ,  Murray TG, Ksander BR: Signals emanating from membrane Fas Ligand control the release of cytoplasmic Fas Ligand and the induction of apoptosis. Invest Ophthalmol Vis Sci 1998;39(4)(Suppl):606.
  113. Verbik DJ, Murray TG, Ksander BR: Primary ocular melanomas are immunosuppressive and non-immunogenic. Invest Ophthalmol Vis Sci 1997;38(4)(Suppl):803.
  114. Chen PW, Murray TG, Ksander BR: Mage expression in ocular melanomas during progression from primary to metastatic disease. Invest Ophthalmol Vis Sci 1997;38(4)(Suppl):464.
  115. Uno T, Murray TG, Chen PW, Podack ER, Ksander BR: Gene transfer of the B7-1 co-stimulatory molecule into human ocular melanoma cells. Invest Ophthalmol Vis Sci 1997;38(4) (Suppl):463.
  116. Cicciarelli N, Murray TG, Markoe A, Hernandez E, Smith BJ, O’Brien JM: Efficacy of subconjunctival carboplatin and external beam radiation (EBRT) in murine retinoblastoma. Invest Ophthalmol Vis Sci 1997;38(4)(Suppl):448.
  117. Murray TG, Cicciarelli N, Hernández E, Smith BJ, O’Brien JM: In vivo efficacy of subconjunctival carboplatin with and without cryotherapy in Murine retinoblastoma. Invest Ophthalmol Vis Sci 1997;38(4)(Suppl):448.
  118. Kaiser PK, Roth DB, Scott IU, Murray TG: Serial echographic characterization of retinoblastoma after radiation therapy, laser photocoagulation, and/or cryotherapy. Invest Ophthalmol Vis Sci 1997;38(4)(Suppl):384.
  119. Del Carmen JF, O’Brien JM, Smith BJ, Murray TG: The initial metastatic evaluation in retinoblastoma. Invest Ophthalmol Vis Sci 1997;38(4)(Suppl):384.
  120. Smith BJ, Murray TG, Cicciarelli N, O’Brien JM: Local chemotherapy using VP-16 and vincristine in murine transgenic retinoblastoma. Invest Ophthalmol Vis Sci 1997; 38(4) (Suppl):147.
  121. Gordon KB, Murray TG, Cicciarelli N, Hernandez E, Smith BJ, Mueller RL, O’Brien JM: Subconjunctival chemotherapy using vincristine, etoposide or cyclophosphamide in a transgenic mouse model of retinoblastoma. Invest Ophthalmol Vis Sci 1997;28(4)(Suppl):147.
  122. Tran JM, Murray TG, Uno T, Valor N, Ksander BR: Expression of HLA class I on ocular melanoma during progression from primary to metastatic disease.  Invest Ophthalmol Vis Sci 1996;37(3)(Suppl):208.
  123. McCabe C, Murray TG, Cicciarelli N, Hernandez E, Windle JJ, Smith B, Schoenike S, Ksander B, O’Brien JM: In vitro efficacy of focal etoposide, vincristine, or cyclophosphamide in murine retinoblastoma. Invest Ophthalmol Vis Sci 1996;37(3)(Suppl):246.
  124. Murray TG, Cicciarelli N, Keller B, Hernandez E, Smith B, Markoe A, Windle JJ, Ksander B, O’Brien JM: In vivo efficacy of external beam radiation therapy as a function of dose fractionation and total radiation dose in murine retinoblastoma. Invest Ophthalmol Vis Sci 1996;37(3) (Suppl):914.
  125. Ksander BR, Murray TG, Uno T, Geer DC, Podack ER, Chen PW: Activation of tumor-specific T cells by human ocular melanoma cells transfected with cDNA for the B7.1 costimulatory molecule. Invest Ophthalmol Vis Sci 1996;37(3)(Suppl):1114.
  126. Chen PW, Uno T, Murray TG, Podack ER, Ksander BR: Gene therapy of ocular melanoma using a novel episomal vector system. Invest Ophthalmol Vis Sci 1996;37(3)(Suppl):1131.
  127. Cicciarelli N, Murray TG, Smith B, Hernandez E, McCabe C, Schoenike S, Windle JJ, Ksander B, O’Brien JM: Murine transgenic retinoblastoma: tumor control as a function of total dose and cycle number for locally delivered carboplatin. Invest Ophthalmol Vis Sci 1996;37(3) (Suppl):1132.
  128. Fine SL, Murray TG: Collaborative Ocular Melanoma Study: 10 year status.  Vitreous Society 1995 Annual Meeting; London, England; August 1995.  (Abstract Presentation)
  129. Chen PW, Salgaller M, Rosenberg SA, Murray TG, Ksander BR: Increased expression of genes encoding tumor specific antigens in ocular melanoma: Potential targets for immunotherapy.  Invest Ophthalmol Vis Sci 1995;36(4)(Suppl):221.
  130. Mieler WF, Steeves RA, Tomkins R, Nash RW, Blair JR, Gentry L, Paliwal B, Murray TG: Concurrent versus sequential ferromagnetic hyperthermia and iodine-125 brachytherapy in the management of melanoma in an animal model. Invest Ophthalmol Vis Sci 1995;36(4) (Suppl):393.
  131. O’Brien JM, Harbour JW, Smith B, Cohen J, Char DH, Kroll S, Murray TG: Utility of initial metastatic tests and serial bone scans in patients with retinoblastoma. Invest Ophthalmol Vis Sci 1995;36(4)(Suppl):494.
  132. Murray TG, Valor N, Hernandez E, Schoenike S, O’Brien JM, Ksander BR: In vivo efficacy of focal carboplatin and hyperthermia in murine retinoblastoma. Invest Ophthalmol Vis Sci 1995;36(4)(Suppl):773.
  133. Geer DC, O’Brien JM, Smith BJ, Murray TG, Valor NL, Ksander BR: Interleukin-12 treatment of retinoblastoma. Invest Ophthalmol Vis Sci 1995;36(4)(Suppl):773.
  134. Harbour JW, Murray TG, Valor N, Hernandez E, Markoe A, Keller B, Schoenike S, Smith B, O’Brien JM: In vivo efficacy of locally delivered carboplatin and external beam irradiation in murine retinoblastoma. Invest Ophthalmol Vis Sci 1995;36(4)(Suppl):774.
  135. Weishaar PD, Flynn HW Jr, Murray TG, Davis JL, Barr CC, Gross JC, Mein CE, McLean WC Jr: Endogenous Aspergillus endophthalmitis: clinical features and treatment outcomes. Invest Ophthalmol Vis Sci 1995;36(4)(Suppl):789.
  136. Cohen SM, Weishaar PD, Murray TG: Effect of photocoagulation on laser power transmission through human retina. Invest Ophthalmol Vis Sci 1995;36(4)(Suppl):833.
  137. Eells JT, Lewandowski MF, Murray TG: Formate-induced retinal dysfunction in methanol-intoxicated rats. Invest Ophthalmol Vis Sci 1994;35(Suppl):1516.
  138. Kim JE, Flynn HW Jr, Smiddy WE, Murray TG, Rubsamen PE, Davis JL, Nicholson DH: Management of retained lens fragments after phacoemulsification using pars plana vitrectomy.  Invest Ophthalmol Vis Sci 1994;35(Suppl):1615.
  139. Sharkey JA, Civantos J, Flynn HW Jr, Rubsamen PE, Nicholson DH, Smiddy WE, Murray TG: The prognosis of giant retinal tears associated with high axial myopia. Invest Ophthalmol Vis Sci 1994;35(Suppl):1615.
  140. Aaberg TM Jr, Potarazu SV, Flynn HW Jr, Murray TG: Intraocular ceftazidime as an alternative to the aminoglycosides in the treatment of endophthalmitis. Invest Ophthalmol Vis Sci 1994;35(Suppl):1910.
  141. Murray TG, Ksander BR, Hamasaki D, Valor N, Hernandez E, Markoe A, Fiedler JA, Schoenike S, O’Brien JM: Efficacy and safety of focally delivered carboplatin and external beam radiation in the treatment of murine retinoblastoma. Invest Ophthalmol Vis Sci 1994;35(Suppl):2084.
  142. Ksander BR, Geer DC, O’Brien JM, Albert DM, Murray TG: Retinoblastoma specific cytotoxic T cells fail to eliminate intraocular tumors. Invest Ophthalmol Vis Sci 1993;34(Suppl):974.
  143. Murray TG, Geer DC, O’Brien JM, Albert DM, Ksander BR: Retinoblastoma cells down-regulate expression of cell-surface class I MHC molecules. Invest Ophthalmol Vis Sci  1993;34(Suppl):1227.
  144. Murray TG, O’Brien JM, Steeves RA, Albert DM: Interaction of ferromagnetic hyperthermia and external beam irradiation in the treatment of murine retinoblastoma. Invest Ophthalmol Vis Sci 1992;33(Suppl):877.
  145. O’Brien JM, Murray TG, Steeves RA, Marcus DM, Brauner E, Albert DM: Application of ferromagnetic hyperthermia in the treatment of murine retinoblastoma. Invest Ophthalmol Vis Sci 1992;33(Suppl):877.
  146. Hartz A, Han DP, Wang Q, Murray TG, Boldt HC, Arrindell E, Jaffe GJ, Coe E, Mieler WF, Abrams GW, Lewis H, Gottlieb M: The association of postvitrectomy fibrin formation with long-term visual outcome. Invest Ophthalmol Vis Sci 1992;33(Suppl):898.
  147. Mieler WF, Murray TG, Steeves RA, Moros EG, Boldt HC: Repetitive ferromagnetic hyperthermia (FMH) achieves enhanced tumoricidal activity. Invest Ophthalmol Vis Sci 1992;33(Suppl):1254.
  148. Han DP, Murray TG, Boldt HC, Palmer M, Abrams GW, Mieler WF: Perfluoro-n-octane: Evaluation of acute anterior segment toxicity with intravitreal use. Invest Ophthalmol Vis Sci 1992;33(Suppl):1313.
  149. Eells JT, Murray TG, Lewandowski MF, Stueven HA, Burke JM: Methanol poisoning: clinical evidence of direct retinal dysfunction. Invest Ophthalmol Vis Sci 1991;32(Suppl):689.
  150. Hyndiuk RA, Murray TG, Palmer M, Boldt HC, Han DP, Mieler WP, Abrams GW: Perfluoro-n-octane: evaluation of anterior segment toxicity associated with intraocular use. Invest Ophthalmol Vis Sci 1991;32(Suppl):880.
  151. Mieler WF, Murray TG, Boldt HC, Zellmer D, Erickson B: Ytterbium-169: experimental evaluation of a new brachytherapy source. Invest Ophthalmol Vis Sci 1991;32(Suppl):979.
  152. Boldt HC, Murray TG, Steeves RA, Moros E, Lewandowski MF, Mieler WF: Combined ferromagnetic hyperthermia and 125I episcleral plaque therapy: studies of therapeutic dose response curves. Invest Ophthalmol Vis Sci 1991;32(Suppl):979.
  153. Murray TG, Boldt HC, Gillin MT, Mieler WF: Sulfur-35 endo-irradiation: dosimetry modeling and experimental efficacy. Invest Ophthalmol Vis Sci 1991;32(Suppl):979.
  154. Abrams GW, Murray TG, Boldt HC, Han DP, Mieler WF: Tissue plasminogen activator (tPA): Determination of clinical limits of efficacy for intracameral delivery. Invest Ophthalmol Vis Sci 1991;32(Suppl):1226.
  155. Eells JT, Rajani C, Murray TG, Lewandowski MF, Burke JM: Methanol-induced ocular toxicity: development of a rodent model. Invest Ophthalmol Vis Sci 1990;31(Suppl):143.
  156. Murray TG, Rajani C, Eells JT, Burke JM: Ocular methanol toxicity: cell type specificity in vitro. Invest Ophthalmol Vis Sci 1990;31(Suppl):286.
  157. Abrams GW, Murray TG, McKay BS, Han DP: Transcorneal tissue plasminogen activator delivery: a functional in vivo study. Invest Ophthalmol Vis Sci 1990;31(Suppl):404.
  158. Burke JM, Murray TG: Regional comparisons of cytochrome oxidase activity in retina and RPE. Invest Ophthalmol Vis Sci 1990;31(Suppl):492.
  159. Eells JT, Murray TG, Rajani C, Lewandowski MF, Burke JM: A rodent model of methanol-induced ocular toxicity. Proc Int Soc Eye Res 1990;6:115.
  160. Rajani C, Murray TG, Burke JM, Eells JT: Inhibition of bovine retinal cytochrome oxidase activity by formic acid. The Pharmacologist 1990;32:162.
  161. Eells JT, Murray TG, Rajani C, Burke JM: Formic acid inhibits cytochrome oxidase activity in retina and in cultured retinal cells. Soc Neurosci 1990;16:611.
  162. Murray TG, Stern WH, MacGowan-Smith E, Balyeat E: Transcorneal heparin delivery: physiology, pharmacokinetics and tissue binding. Invest Ophthalmol Vis Sci 1989;30(Suppl):258.
  163. Kindy-Degnan N, Murray TG, Char DH, Swift P, Kurhanewicz J, Kaleta S:  Assessment of intraocular tumor viability:  a pre- and post-treatment comparison of fine needle biopsy and 31P magnetic resonance spectroscopy. Invest Ophthalmol Vis Sci 1988;29(Suppl):210.
  164. Swift PS, Murray TG, Char DH, Kindy-Degnan N, Fries P: Quantitative effect of hyperthermic treatment on the Greene melanoma. Invest Ophthalmol Vis Sci 1988;29(Suppl):211.
  165. Swift PS, Stauffer PR, Murray TG, Phillips TL, Char DH: Response of choroidal melanoma in rabbits to 2450-MHz microwave hyperthermia. Proc Int Soc Eye Res 1988;5:167.
  166. Aguayo J, Murray TG, Torentino P, Cousins J, Kan L-S, Stark WJ: Maintenance of human lenses in tissue culture and study by 31P NMR spectroscopy. Invest Ophthalmol Vis Sci 1985;26(Suppl):162.

Other Professional Activities:

American Biological Society, May 1981

  • Humphrey G, Murray TG, Pigiet V.  Direct quantification of the large (100K) polyoma T-antigen on the nuclear matrix (poster presentation)

Summer Research Fellowship Program; National Institute of Health; Bethesda, MD; August 1982

  • Murray TG and Joiner K.  Differential complement activation and septic shock

Association of American Medical Colleges, 94th Annual Meeting, Baltimore, MD, November 1983

  • McHugh P, Petty B, Lane M, Lattman E, Margolis S, Murray TG, Nathans D, Seidel H, Yardley J.  Early admission to medical school: a unique approach (poster presentation)

NMR in Medicine Symposium, New York, NY, August 1984

  • Murray TG, Aguayo J, Stark W, Torentino P, Sulewski M.  Viability of the human lens by 31P nuclear magnetic resonance spectroscopy (abstract presentation)

American Society of Microbiology, October 1984

  • Joiner K, Schmetz M, Murray TG, Dourmashkin R, Frank M.  Importance of C9 multiplicity in direct complement-killing of E. Coli J5 (EC) (abstract presentation)

North American Hyperthermia Group, 8th Annual Meeting, April 1987

  • Swift PS, Stauffer PR, Murray TG, Phillips TL, Char DH.  Response of choroidal melanoma in rabbits to 2450-MHz microwave hyperthermia (abstract presentation)

Cordes Eye Society, University of California, San Francisco, San Francisco, CA, 1987

  • Murray TG et al.  Carotid-cavernous fistula and Ehler’s-Danlos syndrome: presentation and interventional radiologic management

Resident’s Day; University of California, San Francisco, San Francisco, CA, May 1988

  • Murray TG et al.  Ocular hyperthermia: characterization of a 2450-MHz microwave hyperthermia unit utilizing a rabbit Greene melanoma model

Resident’s Day; University of California, San Francisco, San Francisco, CA, May 1989

  • Murray TG et al.  Transcorneal heparin delivery

First Midwest Fluorescein Conference, Egg Harbor, WI, August 1989

  • Murray TG et al.  Talc retinopathy/choroidal folds

1990 Winter Retina Symposium, Kohler, WI, February 1990

  • Murray TG et al.  Idiopathic central serous choroidopathy: an update, acquired retinal disease

Resident’s and Fellow’s Day, Eye Institute, Medical College of Wisconsin, Milwaukee, WI, June 1990

  • Murray TG et al.  Methanol toxicity: new investigations into mechanism of neurotoxicity

Grand Rounds presentation, Eye Institute, Medical College of Wisconsin, Milwaukee, WI, July 1990

  • Murray TG et al.  Formate and methanol poisoning: in vivo and in vitro analysis of ocular toxicity

Second Midwest Fluorescein Conference, Egg Harbor, WI, August 1990

  • Murray TG et al.  Bilateral central retinal vein occlusion/choroideremia

1991 Winter Retina Symposium, Kohler, WI, February 1991

  • Murray TG et al.  Ocular sports injuries/protective eye wear
  • Murray TG et al.  Experimental alternatives in the management of uveal melanoma

Kohler Eye Meeting, Kohler, WI, June 1991

  • Murray TG et al.  Perfluorocarbon liquids: new frontiers in vitreous surgery.

Sixth International Congress on Hyperthermic Oncology; Miami, FL, April 1992

  • Steeves RA, Murray TG, Tompkins DT, Nanda S, Paliwal BR, Mieler WF: Thermal enhancements with experimental choroidal melanoma: simultaneous versus sequential hyperthermia and brachytherapy (abstract presentation)

International Symposium on Ocular Tumors, New York, NY, April/May 1992

  • Geer DC, Ksander BR, Murray TG, Rubsamen PE: Tumor-specific immune response to retinoblastomas

28th Annual Residents’ Days, Bascom Palmer Eye Institute, University of Miami, Key Biscayne, FL, June 1992

  • Weishaar PD, Murray TG, Flynn HW Jr: Expanding indications for perfluorocarbon liquids in vitreoretinal surgery

Aspen Retinal Detachment Society, Aspen, CO, March 1993 (invited guest speaker)

  • Murray TG et al.  Immunologic modulation of ocular tumor growth
  • Murray TG et al.  Choroidal hemorrhage/retrobulbar needle penetration

1993 Annual American Association for Cancer Research Meeting, Orlando, FL, April 1993

  • Ksander BR, Geer DC, Murray TG: Studies of tumor-infiltrating-lymphocytes from human retinoblastoma (abstract presentation)

1993 Annual American Association for Cancer Research Meeting, Orlando, FL, April 1993

  • Murray TG, Steeves RA, Mieler WF.  Repetitive versus single ferromagnetic hyperthermia treatments for choroidal melanomas in rabbits (abstract presentation)

Association for Research in Vision and Ophthalmology 1993 Annual Meeting, Sarasota, FL, May 1993

  • Session Moderator – Retinoblastoma

29th Annual Residents’ Days, Bascom Palmer Eye Institute, University of Miami, Coral Gables, FL, June 1993

  • Hummer J, Murray TG. Retinoblastoma: Historical perspective and future trends, the Bascom Palmer experience
  • Luetkemeyer J, Murray TG. Use of the laser aiming beam in differentiating retinoschisis from retinal detachment
  • Civantos J, Murray TG. Management of giant retinal tears in phakic eyes

Trade Secrets, Bascom Palmer Eye Institute, University of Miami, Ocular Tumors, Miami, FL; June 1993

  • Murray TG et al.  Vitrectomy for Macular Disease
  • Murray TG et al.  Differential diagnosis of pigmented lesions of the retina

Asociación Oftálmologica del Norte, San Sebastian, Spain, June 1993

  • Murray TG et al.  Ocular tumors (abstract presentation)
  • Murray TG and Nicholson DH: Treatment of the retinal detachment

Vitrectomy Workshop, Miami, FL, October 1993

  • Murray TG et al.  Prognosis and results
  • Murray TG et al.  Vitreous substitutes: gas, oil, and perfluorocarbon liquids
  • Murray TG et al.  Pars plana vitrectomy-related pathology and basics

Health Professional Course, Miami, FL, November 1993

  • Murray TG et al.  Diabetic retinopathy (invited guest speaker)

Ophthalmic Update 1994, Miami, FL, January 1994

  • Murray TG et al.  Retinoblastoma (invited guest speaker)
  • Murray TG et al.  Melanoma study: radioactive plaque insertion

1994 Medical Retina Course, Palm Beach, FL, March 1994

  • Murray TG et al.  Diagnosis and treatment of ocular tumors

Sylvester Comprehensive Cancer Center, Miami, FL, April 1994

  • Murray TG et al.  Surgical approaches to retinoblastoma (Grand Rounds presentation)

1994 Annual American Association for Cancer Research Meeting, San Francisco, CA, April 1994

  • Murray TG, Geer DC, O’Brien JM, Albert DM, and Ksander BR. Retinoblastoma cells down-regulate expression of cell-surface class I MHC molecules (abstract presentation/poster session)
  • Murray TG, Steeves RA, Gentry L, Tompkins R. Preservation of ocular function and anatomy after ferromagnetic hyperthermia (abstract presentation/poster session)

University of California, San Francisco, San Francisco, CA, April 1994

  • Murray TG et al.  Posterior segment complications of anterior segment surgery (Grand Rounds presentation)

Association for Research in Vision and Ophthalmology Annual Meeting, Sarasota, FL, May 1994

  • Session Moderator – Intraocular tumors

Health Professional Course, Miami, FL, May 1994

  • Murray TG et al.  Diabetic retinopathy

Sixth International Symposium on the Immunology and Immunopathology of the Eye, Washington, DC, June 1994

  • Davis T, Ruiz P, Viciana A, Thompson W, Murray TG. Flow cytometry of diagnostic vitrectomy specimens (abstract presentation/poster session)

30th Annual Residents’ Days, Bascom Palmer Eye Institute, University of Miami School of Medicine, Key Biscayne, FL, June 1994

  • Chang T, Gass JDM, Murray TG, Frazier-Byrne S, Hughes R. Echographic findings in lymphoid neoplasia of the choroid  (abstract presentation)
  • Sharkey JA, Murray TG. Etiology and treatment of secondary retinal angiomas (abstract presentation)
  • Weishaar P, Cohen SM, Murray TG. Effect of photocoagulation on laser power transmission through human retina  (abstract presentation)

Vitreous Society Annual Meeting, Aspen, CO, August 1994

  • Murray TG, Kim JE, Flynn HW Jr, Smiddy WE, Davis JL, Nicholson DH, Rubsamen PE. Retained lens fragments after phacoemulsification (abstract presentation)
  • Murray TG, Frazier-Byrne S, Hughes JR, Gendron EK.  Intraoperative
  • echographic localization for posterior uveal melanoma 125I brachytherapy treatment   (abstract presentation)
  • Foster RE, Martinez J, Murray TG, Rubsamen PE, Flynn HW Jr, Forster RK. Good  visual outcome following treatment of bacillus cereus endophthalmitis  (abstract presentation)
  • Flynn HW Jr, Cohen SM, Murray TG, Smiddy WE. Endophthalmitis after Vitrectomy Study Group: Endophthalmitis after pars plana vitrectomy  (abstract presentation)

Trade Secrets: Ophthalmology for the Non-Ophthalmologist, Miami, FL, September 1994

  • Murray TG et al.  Diabetes and the eye

American Society of Ophthalmic of Registered Nurses, Miami, FL, February 1995

  • Murray TG et al.  Vitrectomy for macular diseases

Health Professional Course, Miami, FL, March 1995

  • Murray TG et al.  Diabetic retinopathy

Palm Beach Vitreoretinal Course, Manalapan, FL, March 1995

  • Murray TG et al.  Tumor management and therapy

Palm Beach Vitreoretinal Course, Manalapan, FL, March 1996

Mechanisms of Disease Course, Miami, FL, April 1996

  • Murray TG et al.  Ocular oncology.

Otolaryngology & Ophthalmology for the Generalist, Miami, FL, Jan 1997

  • Murray TG et al.  Melanoma, Advances in Clinical Management and Research

Update on Small Ocular Melanoma Trial, COMS Technical Group Meeting, Denver, CO, March 1997.

Aspen Retinal Detachment Society Meeting, Aspen, CO, March 1997

  • Murray TG et al.  Melanoma, Advances in Clinical Management and Research
  • Murray TG et al.  Retinoblastoma, Advances in Clinical Management and Research

Vitreoretinal Course, Bascom Palmer Eye Institute, University of Miami School of Medicine, Ft. Lauderdale, FL, May 1997.

  • Murray TG et al.  Current Status of Melanoma Management

33rd Annual Residents’ Days Bascom Palmer Eye Institute, University of Miami School of Medicine, Coral Gables, FL, June 1997

  • Murray TG et al.  Retinoblastoma: Lessons from the Lab

ASORN Meeting, San Francisco, CA, October 1997

  • Murray TG et al.  Vitrectomy Surgery: The Basics
  • Murray TG et al.  Vitrectomy for Macular Diseases

Ophthalmic Photographers Society Meeting, San Francisco, CA, October 1997

  • Murray TG et al.  Clinical Trials and Protocols

American Academy of Ophthalmology meeting, San Francisco, CA, October 1997

  • Murray TG et al.  Combined Pars Plana Vitrectomy, Cataract Extraction & Intraocular Lens Insertion

International Eye Foundation, Ophthalmology/Oncology Seminar, Guatemala, August 1998 (invited guest speaker)

  • Advances in Management of Pediatric Intraocular Malignancies
  • Posterior Segment Complications of Anterior Segment Surgery
  • Pediatric Orbital Malignancies
  • Clinical Case Series: Pediatric Retina
  • Advances and Controversies in Management of Posterior Uveal Melanoma
  • Clinical Case Series: Retinoblastoma
  • Acute Lymphocytic Leukemia: Advances in Management

XXIst Meeting of the Club Jules Gonin, Edinburgh, Scotland, Aug 28-Sept 1, 1998

  • Chaudhry NA, Murray TG: Simultaneous cataract extraction and pars plana vitrectomy for proliferative diabetic retinopathy (abstract/poster presentation)

Cincinnati Ophthalmological Society meeting, Cincinnati, OH, Sept 8, 1999 (invited guest)

  • Retinoblastoma
  • Posterior segment complications of anterior segment

Vitreous Society, Rome, Italy, Sept 21-26, 1999

American Academy of Ophthalmology Meeting, Orlando, FL, Oct 21-26, 1999

  • ASORN Retinal Course

XII Inter-American Course, Miami, FL, Oct 31, 1999 (invited guest)

  • Murray TG et al.  Anterior segment surgery II: choroidal hemorrhage, endophthalmitis

Texas Retina Society, Austin, TX, Nov 11, 1999 (invited guest)

  • Murray TG et al.  Melanoma

American Board of Ophthalmology, Nov 12-14, 1999 (preceptor)

Retina Society, Hawaii, Nov 27-Dec 4, 1999

Miami Beach Kiwani’s Club, Miami Beach, FL, Jan 20, 2000 (invited guest)

  • Retinoblastoma

Trade Secrets, Bascom Palmer Eye Institute, Miami, FL, Jan 29, 2000

  • Murray TG et al.  Current concepts in posterior uveal melanoma

Macula Society, Puerto Rico, Feb 23-26, 2000

Collaborative Ocular Melanoma Study meeting, Texas, Mar 24-25, 2000

Association for Research in Vision and Ophthalmology (ARVO), Ft. Lauderdale, FL, Apr 30-May 5, 2000

  • Murray TG et al.  An in vivo comparison of systemic versus focal chemotherapy in the management of RB

36th Annual Residents’ Days, Bascom Palmer Eye Institute, Miami, FL, June 17, 2000

  • Murray TG et al.  Research and clinical advances in management of retinoblastoma

ACOSOG meeting, Chicago, IL, June 23-24, 2000

  • 6/23/00 Eye Organ Site Committee meeting
  • 6/24/00 Melanoma Organ Site Committee meeting

Vitreous Society, July 3-7, 2000

AMDRT DSMC Meeting, Philadelphia, PA, August 3, 2000

Club Jules Gonin Society meeting, Taormina, Italy, September 2-6, 2000

  • Murray TG et al.  Acute complications of globe conserving therapy in advanced retinoblastoma

Alcon Retinal Advisory Council 2000 meeting, Las Colinas, TX, October 18-19, 2000

American Academy of Ophthalmology Subspecialty Day [Retina], Dallas, TX, October 20, 2000

American Academy of Ophthalmology annual meeting, Dallas, TX, October 2000

  • Murray TG et al.  Retcam
  • Murray TG et al.  Clinical trials for OPS
  • Murray TG et al.  Widefield imaging of pediatric retinal diseases: a photographer’s approach

CURSO Annual meeting, Miami, FL, November 11, 2000

  • Murray TG et al.  Current indications and techniques of subretinal surgery
  • Murray TG et al.  Advances in intraocular tumor management

Retina Society meeting, Miami, FL, December 2000

  • Murray TG et al.  Globe conserving iodine 125 episcleral plaque radiotherapy of large, diffuse choroidal melanoma

American Academy of Optometry meeting, Orlando, FL, December 7, 2000

  • Murray TG et al.  Advances and controversies in the treatment of choroidal neovascular membranes
  •  Murray TG et al.  Advances and controversies in retinal and vitreoretinal disease

Vitreous Society meeting, Cancun, Mexico, January 9-11, 2001

  • Murray TG et al.  Pars plana lensectomy and intraocular lens implantation in pediatric radiation-induced cataracts in retinoblastoma
  • Moderator – Ocular Oncology and Uveitis

Retina 2001 meeting, Kauai, HI, January 21-26, 2001

  • Murray TG et al.  Widefield imaging of retinopathy of prematurity/retinoblastoma
  • Murray TG et al.  Retinal emergencies
  • Murray TG et al.  Current approach to retinoblastoma
  • Murray TG et al.  Current approach to malignant melanoma
  • Murray TG et al.  Management of nuclear fragments and dislocated intraocular lenses

Koplowitz Memorial Lecture, Wilmer Eye Institute, Philadelphia, PA, February 9, 2001 (invited lecturer)

  • Advances and controversies in the management of retinoblastoma

Aspen Retinal Detachment Society Meeting, Aspen, CO, March 5-9, 2001

  • Murray TG et al.  Advances in the diagnosis & therapy of uveal melanoma

Collaborative Ocular Melanoma Study Technical meeting, Dener, CO, March 22-26, 2001

  •  COMS-QOLS Advisory Committee meeting, March 25, 2001

Vitreous Society Board of Directors meeting, Las Colinas, TX, March 31, 2001

2001 Vitreoretinal Update, Bascom Palmer Eye Institute, Miami, FL, April 27-28, 2001

  • Murray TG et al.  Combined vitrectomy and cataract surgery
  • Murray TG et al.  Retcam images in pediatric retinal diseases
  • Murray TG et al.  Plaque therapy for choroidal melanoma

Association for Research in Vision and Ophthalmology (ARVO), Ft. Lauderdale, FL, May 1-2, 2001

  • Murray TG et al.  External beam radiation “salvage” therapy in the treatment of murine transgenic retinoblastoma (poster presentation)
  • Murray TG et al.  Carboplatin coulomb controlled iontophoresis (CCI): evaluation of ERG & histopathology (poster presentation)
  • Pharmacokinectics of subconjunctivally administered cyclosporine A: local delivery prior to chemotherapy for retinoblastoma (poster presentation)
  • Translational research in ocular oncology: from bench to bedside (paper presentation)
  • Intraoperative use of perfluoro-n-octane in the repair of complex RD: a prospective, multicenter, observational study (poster presentation)
  • Differential induction of apoptosis in the treatment of murine transgenic RB (paper presentation)
  • Factors associated with visual loss on long-term follow-up in patients with ICSC (poster presentation)
  • Evaluation of the feasibility of macular translocation surgery by laser-induced scleral shortening (poster presentation)

Memorial Sloan Kettering Grand Rounds, New York, NY, 5/17/01 (Guest speaker)

  • Advances & controversies in the management of pediatric retinoblastoma

Xth International Congress of Ocular Oncology, Amsterdam,

The Netherlands, 6/17-21/01

  • Murray TG et al.  External beam radiation “salvage” therapy in the treatment of murine transgenic retinoblastoma: induction of apoptosis

37th Annual Residents’ Days, Bascom Palmer Eye Institute, Miami, FL, 6/22-23/01

  • Murray TG et al.  Prognostic value of staging for uveal melanoma
  • Murray TG et al.  New macular retinoblastoma tumors in patients with previously diagnosed bilateral retinoblastoma

Invited speaker, Michigan Ophthalmological Society, 33rd Annual Conference, Traverse City, MI, 8/2-5/01

  • Advances in choroidal melanoma management
  • Posterior segment complications of anterior segment surgery
  • Retinoblastoma: clinical case series

American Board of Ophthalmology, Cambridge, MA, 10-26-28/01

American Academy of Ophthalmology, Retina subspecialty meeting, New Orleans, LA, 11/9-10/01

  • Murray TG et al.  Retinoblastoma 2001

American Academy of Ophthalmology, New Orleans, LA, 11/11-14/01

  • New data from the COMS
  • Uveal melanoma
  • Metastatic tumors
  • Advances in fundus imaging
  • Radiation therapy
  • Survival outcomes
  • Quality of life determination
  • COMS
  • Retinoblastoma 2001: present and future
  • Pediatric wide-field imaging

XXIII Curso Interamericana, Miami, FL, 11/17-20/01

  • Murray TG et al.  Tumor Update

Vitreous Society, Puerto Rico, 11/28-12/2/01

  • Murray TG et al.  Globe conserving therapy in retinoblastoma
  • Discussant on panel: The good, the bad and the ugly in vitreous surgery

Bascom Palmer Eye Institute 40th Anniversary Scientific Meeting, Miami, FL, 2/21-23/02

  • Moderator: Intraocular Tumors section
  • Retinopathy of Prematurity/Pediatric Retinal Disease Panel

International Symposium on Ocular Pharmacology & Pharmaceutics, Seville, Spain, 2/28-3/3/02 (invited guest)

  • Pharmacokinetics of systemic versus focal carboplatin chemotherapy in the treatment of retinoblastoma

Aspen Retinal Detachment Society meeting, Aspen, CO, 3/5-7/02

COMS Technical Group meeting, Baltimore, MD, 3/17-19/02

BCSC Section 4 meeting, Phoenix, AZ, 4/6-7/02

Vitreous Society Board Meeting, Dallas, TX, 4/13/02

International Congress of Ophthalmology meeting, Sydney, Australia, 4/21-26/02

  • Murray TG et al.  Chemotherapy for retinoblastoma, its present role, including the roles of cyclosporin A and periocular chemotherapy
  • Murray TG et al.  New insights with OCT

Association for Research in Vision and Ophthalmology (ARVO), Ft. Lauderdale, FL, 5/5-10/02

  • Murray TG et al.  Microarray analysis of differential gene expression in autologous primary and metastatic uveal melanoma
  • Murray TG et al.Combretastatin A4 prodrug: subconjunctival delivery of an angiogenesis inhibitor in the treatment of a murine model of retinoblastoma
  • Murray TG et al.  Advances in ocular oncology and application of translational research (poster presentation)
  • Murray TG et al.  Retinal detachment in eyes undergoing pars plana vitrectomy for removal of retained lens fragments (poster presentation)
  • Murray TG et al.  Cellular viability in choroidal melanoma following brachytherapy with subsequent enucleation (poster presentation)
  • Murray TG et al.  Globe conserving therapy in retinoblastoma: comparison of time course of tumor reduction for primary chemoreduction versus external beam radiotherapy (poster presentation)
  • Murray TG et al.  Time course dependent apoptosis following subconjunctival carboplatin therapy in the treatment of murine transgenic retinoblastoma (poster presentation)
  • Murray TG et al.  Magnetically integrated microporous implant: safety and efficacy of secondary stainless steel posting following enucleation surgery (poster presentation)
  • Murray TG et al.  Outcomes of surgery for retinal detachment associated with proliferative vitreoretinopathy using perfluoro-n-octane: a multicenter study (poster presentation)

Macula Society Meeting, Barcelona, Spain, 6/12-15/02

  • Murray TG et al.  Globe Conserving (Salvage) Therapy in the Management of Macular Transgenic Retinoblastoma: The Role of Apoptotic Activation (poster presentation)

38th Annual Residents’ Days, Bascom Palmer Eye Institute, Miami, FL, 6/21/02

Alcon Retinal Advisory Committee (RAC) II Meeting, Palm Beach, FL, 8/16-18/02

Club Jules Gonin Society meeting, Montreux, Switzerland, 8/31-9/4/02

  • Murray TG et al.  Prospective observational study of small/suspicious choroidal melanoma (poster presentation)

Combined Vitreous Society & Retina Society meeting, San Francisco, CA, 9/29-10/3/02

  • Murray TG et al.  Single Use (Disposable) Advanced Vitreoretinal Microsurgical Instruments
  • Murray TG et al.  Prospective observational study of small/suspicious choroidal melanoma
  • Moderator for Ocular Oncology/Lasik/Systemic Therapy Session

American Academy of Ophthalmology, Orlando, FL, Subspecialty Day 10/18/02

  • Murray TG et al.  Retinoblastoma: What’s new for 2002

American Academy of Ophthalmology, Orlando, FL, 10/20-23/02

  • Breakfast with the Experts – Uveal Melanoma and Retinoblastoma Update
  • Instruction Course – Retinoblastoma 2002: Present and Future
  • Murray TG et al.  Outcomes of Surgery for Retinal Detachment Associated with Proliferative Vitreoretinopathy Using Perfluoro-N-Octane (poster presentation)
  • Murray TG et al.  Outcomes and Complications Associated with Giant Retinal Tear Management using Perfluoro-N-Octane (poster presentation)
  • Salvage External Beam Radiotherapy of Retinal Hemangiomas Secondary to Von Hippel-Lindau Disease (poster presentation)

American Board of Ophthalmology exams, San Francisco, CA, 11/8-10/02

  • Examiner

Macular Society meeting, Naples, FL, 2/25-3/1/03

  • Murray TG et al.  Globe conserving (salvage) therapy in the management of macular transgenic retinoblastoma: the role of apoptotic activation

Aspen Retinal Detachment Society meeting, Aspen, CO, 3/2-6/03

Pittsburgh Ophthalmology Society meeting, invited speaker, Pittsburgh, PA, 3/21-22/03

  • Murray TG et al.  Ocular oncology update: focus on COMS outcomes and new treatments in primary retinoblastoma
  • Murray TG et al.  Posterior segment complications associated with anterior segment surgery
  • Murray TG et al.  Advances in surgical management of diabetic retinopathy

Bascom Palmer Eye Institute Aspen meeting, Aspen, CO, 4/3-5/03

  • Murray TG et al.  Advances in diagnosis and management of ocular melanoma
  • Murray TG et al.  Advances in widefield digital pediatric imaging
  • Murray TG et al.  Advances in diagnosis and management of pediatric retinoblastoma

Lecture to Ophthalmic Technicians, Bascom Palmer Eye Institute, Miami, FL, 4/12/03

  • Ocular oncology

Bascom Palmer Eye Institute Vitreoretinal meeting, Miami, FL, 5/2/03

  • Imaging studies/case presentations
  • COMS update

Association for Research in Vision and Ophthalmology (ARVO), Ft. Lauderdale, FL, 5/4-9/03

  • Murray TG et al.  Continuous vs. non-continuous laser photocoagulation for the treatment of threshold ROP
  • Co-moderator: Anatomy and Pathology session
  • Murray TG et al.  Anecortave Acetate, an Angiostatic Steroid, in the Treatment of a Murine Model of Retinoblastoma
  • Murray TG et al.  FNAB in the evaluation of atypical uveal effusion syndrome: histopathological review (poster presentation)
  • Murray TG et al.  Immediate postoperative use of single topical agent to prevent IOP elevation after PPV with long acting gas tamponade (poster presentation)
  • Murray TG et al.  CME in eyes undergoing PPV for retained lens fragments (poster presentation)
  • Murray TG et al.  Correlation between Optos ultra widefield digital imaging, standardized fundus photography, and b-scan echography in the detection of posterior segment tumors (poster presentation)

RB & Genetic Eye Disease meeting, Paris, France, 5/19-22/03

  • Combretastatin A4 prodrug, an angiogenesis inhibitor in the treatment of the murine model of RB (poster presentation)

Bascom Palmer Eye Institute’s Annual Residents’ Days, Miami, FL, 6/20-22/03

Vth G.I.V.R.E. meeting, Reggio Calabria, Italy, 6/27-28/03

  • Murray TG et al.  Combined pars plana vitrectomy & lens management in complex vitreoretinal disease

American Society of Retina Specialists meeting, New York, NY, 8/16-20/03

COMS QOLS Advisory Committee meeting, Denver, CO, 9/4-6/03

3rd Southwest Vitreoretinal Symposium with Fellow’s Forum, San Antonio, TX, 10/17-19/03

  • Murray TG et al.  Wide-Field Viewing in Pediatric Retinal Diseases
  • Murray TG et al.  Diagnostic and Therapeutic Dilemmas in Pediatric Retinal Detachment
  • Murray TG et al.  Globe Conserving Therapy in the Management of Retinoblastoma
  • Murray TG et al.  Application of Clinical Trial Data in the Management of Uveal Melanoma

COG Retinoblastoma Symposium, Dallas, TX, 11/7/03

Bascom Palmer Eye Institute, McKnight Research Retreat, Miami, FL, 1/10/04

Association for Research in Vision and Ophthalmology (ARVO), Program Committee meeting, Baltimore, MD, 1/23-24/04

BPEI Angiogenesis 2004 meeting, Miami, FL, 2/6-7/2004

  • Murray TG et al.  Antiangiogenic therapy for ocular tumors

27th Macula Society Meeting, Las Vegas, NV, 2/25 – 2/28/04

  • Murray TG et al.  Novel anti-angiogenic treatment of murine transgenic retinoblastoma

Aspen Retinal Detachment Society Meeting, Aspen, CO, 2/29-3/4/04

  • Murray TG et al.  Current Directions in Ocular Oncology
  • Murray TG et al.  My approach to vitrectomy combined with scleral buckle

Grand Rounds, University of California, San Francisco, 3/25-26/04

  • Murray TG et al.  Anti-angiogenesis in primary RB: a novel therapeutic approach
  • Murray TG et al.  Posterior segment complications of anterior segment surgery

14th Duke Advanced Vitreous Surgery Course, Durham, NC, 4/22-24/04

  • Murray TG et al.  Widefield Imaging in Pediatric Retinal Disease
  • Murray TG et al.  Advanced Concepts in the Management of Pediatric RB
  • Murray TG et al.  Advanced Concepts in the Management of Complex Uveal Melanoma
  • Murray TG et al.  Complex Surgical Approaches to Advanced Vitreomacular Pathology

Association for Research in Vision and Ophthalmology (ARVO), Ft. Lauderdale, FL, 4/25-30/04

  • Moderator: Imaging: Anatomy & Pathology Session
  • Murray TG et al.  Combined anti-angiogenic and periocular chemotherapy utilizing anecortave acetate & carboplatin in the treatment of retinal tumors in the LH betaTag murine transgenic model of RB

Alcon Advisory Board Meeting, Carlsbad, CA, 8/13-15/04

American Society of Retina Specialists, San Diego, CA, 8/16-20/04

  • Murray TG et al.  Vascular targeting (anecortave acetate) & carboplatin chemotherapy enhance tumor control in murine RB (poster presentation)
  • Moderator: Symposium 7: Ocular Oncology/Infectious Diseases/Endophthalmitis

American Academy of Ophthalmology, New Orleans, LA, 10/22-27/04

  • Retina 2004, Discussion Group Leader
  • Murray TG et al.  Phakomatoses
  • Murray TG et al.  Pharmacotherapies for Ocular Tumors
  • Moderator, Autofluorescence in small uveal melanocytic lesions
  • Moderator, Macular RB managed with chemoreduction: analysis of tumor        control with or without adjuvant thermotherapy in 68 tumors

XXVI Inter-American Course, Miami, FL, 10/31-11/3/04

  • Widefield Imaging

Association for Research in Vision and Ophthalmology (ARVO) PC meeting, Bethesda, MD, 1/21-22/05

Association of Pediatric Retinal Surgeons Meeting, Hawk’s Cay, Florida Keys, 1/27-30/05

  • Murray TG et al.  Advancement of pharmacotherapies in the management of pediatric retinoblastoma

Macula Society meeting, Key Biscayne, FL, 2/23-26/05

  • Murray TG et al.  Macular retinoblastoma: enhancement of tumor control with             immediate, consecutive laser thermotherapy
  • Murray TG et al.  Translation approaches to treatment advances in         retinoblastoma: the role of the clinician scientist

Aspen Retinal Detachment Society meeting, Aspen, CO, 3/6-11/05

AAO Mid-year Forum, Washington, DC, 4/6-9/05

Genentech Meeting, Washington, DC, 4/15-16/0

Bascom Palmer Eye Institute 2005 Vitreoretinal Course, Miami, FL, 4/29-30/05

Retinal Advisory Committee II meeting, Washington, DC, 5/13-15/05

Bascom Palmer Eye Institute Annual Resident’s Day Meeting, 6/17-18/05

  • Moderator, Pediatric Tumors Session

American Society of Retina Specialists meeting, Montreal, International RB Symposium, Fairmont Hotel, Whistler, Canada, 9/1-5/2005

  • Murray TG et al.  Characterization of VEGF Receptor Two expression in the   Retinoblastoma mouse model LHbTAG.
  • Murray TG et al.  Vascular Targeting Enhances Focal Chemotherapy in the       Control of Retinoblastoma Tumor Burden.
  • Schefler AC, Murray TG.  Macular Retinoblastoma: Evaluation of Tumor         Control, Local Complications, and Visual Outcomes for Eyes treated with Chemotherapy and Repetitive foveal laser ablation
  • Murray TG et al.  Gelatinase Modulation as Treatment for Retinoblastoma        (poster presentation)

Retina Society Meeting, Coronado, CA 9/15-18/2005

American Academy of Ophthalmology, Chicago, IL 10/14-19/2005

  • Luncheon Discussion Group Schedule–V17: Intraocular Tumor Management   Update, Discussion Group Leader.
  • Murray TG et al.  Macular Retinoblastoma Enhancement of Tumor Control      with Intermediate Consecutive Laser Thermal Therapy
  • Advanced Vitreoretinal Technology and Therapies Symposium
  • Moderator, Breakfast with the Experts roundtable (Ocular Oncology Update)
  • Murray TG et al.  Safety and Efficacy of Intravitreal Triamcinolone Acetonide            for Macular Edema in Central Retinal Vein Occlusion: One Year Results.
  • Murray TG et al.  Current and new concepts for the ideal socket and     prosthesis.
  • Moderator, 2005 Breakfast with the Experts Roundtable B329 (Pharmacotherapies for Ocular Tumors)
  • Murray TG et al.  Outcomes of Vitrectomy for retained lens fragment (poster   presentation)
  • Murray TG et al.  An Impact Study on the management of retinoblastoma
  • Murray TG et al.  Whole Body PET/CT Imaging for Choroidal Melanoma
  • Murray TG et al.  The potential use of Fibrin Sealant delivery of periocular       chemotherapy.

BPEI 2006 Research Retreat 01/06/06

BPEI Angiogenesis 2006, Miami, FL 02/04-05/2006

  •  Murray TG et al.  Intraocular Tumor Microvascular Targeting Enhances            Tumor Control in Retinoblastoma: In Vivo Modeling of Treatment      Parameters.

Miami Nature Biotechnology Winter Symposium, Miami, FL 02/04-5/2006

34th Annual Aspen Retinal Detachment Society Meeting, Aspen, CO 03/05-09/2006

ASRS 2006 Mid-Year Board Meeting, Las Vegas, NV April 22, 2006

2006 Retinal Physician Symposium, The Atlantis Paradise Island, Bahamas, May 31 – June 3, 2006 (Invited Speaker)

  • Retinoblastoma Update
  • Experimental Therapies for Tumors- Ready for Prime time

ABO Oral Examinations. San Francisco, CA, June 9 – 11, 2006

  • Invited Examiner

2006 BPEI Resident’s Day – Miami, FL, June 16-17, 2006

18th Annual Midwest Ocular Angiography Conference, Girdwood, Alaska 8/2-5/06

24th Annual ASRS Meeting, Cannes, France 9/9-13/06

American Academy of Ophthalmology, Las Vegas, Nevada, 11/11-14/06

  • Academy Subspecialty Day – Discussion Group Leader
  • Temporary Complete VEGF-A Blockage Study Group
  • Murray TG et al.  Retinoblastoma Treatment Update

Association of Pediatric Retinal Surgeons Meeting, Jan 18-21, 2007

  • Murray TG et al.  Implications of Retinoblastoma Tumor Vasculature on           Novel Therapies

Angiogenesis 2007, Miami, Florida, Feb 23-24, 2007

  • Murray TG et al.  Antiangiogenic Therapy for Ocular Tumors

35th Annual Aspen Retinal Detachment Society Meeting, March 3 – 10, 2007

  • Murray TG et al.  Implications of “Off-label” Therapy in Retinal Disease           Management
  • Murray TG et al.  Ocular Oncology:  Revisiting the Controversies

Retinal Physician Symposium, Sanibel, Florida, April 12-15, 2007

  • Tumors: Adult Tumor Update
  • Tumors: Tumor cases Panel

Royal Australian & New Zealand College of Ophthalmologists, April 26-29, 2007

  • Murray TG et al.  Macular surgery:  Advances in imaging, surgical         technology and techniques
  • Murray TG et al.  Ocular tumor management:  Applications from the     laboratory to the patient
  • Murray TG et al.  Posterior segment complications of anterior segment surgery
  • Murray TG et al.  Complex retinal detachment repair:  The new and the old

2007 Vitreoretinal Update Course, Bascom Palmer Eye Institute, Miami, Florida, May 4-5, 2007

  • Murray TG et al.  Choroidal Melanoma: Pearls Long After the COMS
  • Murray TG et al.  Vascular Biology of Retinoblastoma Implications for Novel Treatments

Association for Research in Vision and Ophthalmology (ARVO), Fort Lauderdale, FL, May 6- 10, 2007

  • Murray TG et al.  Blood Vessel Maturation in Human Uveal Melanoma: Spatial Configuration of Endothelial Vessel Maturation and Neovasculature and Its Impact on Ocular Treatment
  • Murray TG et al.  Uveal Melanoma Cell-Based Vaccines Activate CD4+ T       Lymphocytes That Cross-React With Primary and Metastatic Uveal Melanoma Cells
  • Murray TG et al.  Candida Endophthalmitis Following Cataract Surgery:          Management Strategies, and Visual Acuity Outcomes
  • Murray TG et al.  Echographic Localization of Periocular Carboplatin in           Advanced Retinoblastoma
  • Murray TG et al.  Basic Fibroblast Growth Factor Expression in            Retinoblastoma Progression and Survival
  • Murray TG et al.  Targeting the Tumor Microenvironment as a Therapeutic       Strategy for Retinoblastoma
  • Murray TG et al.  Role of Tumor Associated Macrophages in Retinoblastoma Tumor Growth
  • Murray TG et al.  Quantitative Imaging of Eye Tumor in the Mouse Model of Retinoblastoma With Spectral-Domain Optical Coherence Tomography
  • Murray TG et al.  The Wnt Signaling Pathway Has Tumor Suppressor Properties in Retinoblastoma
  • Murray TG et al.  Differential Induction of Apoptosis in the Treatment of        LHBETATAG Retinoblastoma Following Vessel Targeting
  • Murray TG et al.  Regional Hypoxia in LHBetaTag Murine Retinoblastoma:     Implication for Novel Treatments

Macula Society, London, England, May 30-June 2, 2007

  • Murray TG et al.  Intravitreal Avastin in the Management of Post-Brachytherapy Radiation Retinopathy in Patients with Posterior Uveal Malignant Melanoma

Reggio Retina 2007, Reggio, Italy, June 6 -10, 2007

  • Advanced Pharmacologic Therapy for Intraocular Tumors
  • Uveal Melanoma Advances in Radiotherapy: A Ten Year Update

International Society of Ocular Oncology (ISOO), Siena, Italy, June 27-30, 2007

  • Murray TG et al.  Apoptotic cell death in LHBetaTag tumors following vessel targeting therapy
  • Murray TG et al.  Regional hypoxia in LHBetaTag murine retinoblastoma:        implications for novel treatments.
  • Murray TG et al.  Characterization of tumor associated macrophages in the       LHBetaTage mouse model of retinoblastoma

AVTT/Fellow’s Symposium, Chicago, Illinois, Sept. 7-9, 2007

  • Murray TG et al.  Small Gauge Surgery for Management of Dislocated Lens    Nucleus Fragments

40th Annual Meeting of the Retina Society, Sept. 27-30, 2007

  • Session Moderator – Tumors
  • Murray TG et al.  Long-term Survival Outcomes for Patients Undergoing Observational Management Prior to Definitive 125-Iodine Brachytherapy:  Ten-year Follow-up of a Prospective Treatment Cohort

Iowa Clinical Conference – Visiting Professor, Oct. 3 – 7, 2007

  • Ocular Oncology Update:  Focus on translational research application to advanced patient care
  • Vitreoretinal Surgical Update:  Microincisional surgery – The new and the old

Alcon Meeting, Oct. 19-21, 2007

American Board of Ophthalmology Oral Examinations, Oct 26 – 28, 2007

  • Invited Special Examiner

American Academy of Ophthalmology, New Orleans, Louisiana, Nov. 11-13, 2007

  • Academy Subspecialty Day – Discussion Group Leader
  • Murray TG et al. Sandwich Therapy for Choroidal Melanomas
  • Advanced Vitreoretinal Technology and Therapies Symposium
    • Moderator
    • Murray TG et al. Best Practices for 23-gauge  Success: A Surgeon’s Perspective
    • Alcon Speaker Forum – Micro-Incision Vitrectomy Surgery – Panel Discussion
    • OPS Lecture (Wide Field Pediatric Imaging)

Sylvester Comprehensive Cancer Center Retreat, Marco Island, Florida, Nov. 16-18, 2007

  • Murray TG et al. Advances in Pediatric Retinoblastoma Management Application of Translational Research

American Society of Retina Specialist Meeting, Indian Wells, California, Dec. 1-5, 2007

  • A Roadmap to Emerging Anti-VEGF Therapies:  Driving a Successful Practice Management System
  • Murray TG et al. Juxtapapillary Choroidal Malignant Melanoma:  Custom Notched Plaque 125 Iodine Brachytherapy: a Completed 5 year Pilot clinical Trail

Angiogenesis, Miami, Florida, February 22 – 23, 2008

  • Murray TG et al. Hypoxia Modulation Improves Vessel Targeting in Retinoblastoma

36th Annual Aspen Retinal Detachment Society Meeting, Aspen, Colorado,  March 2-6, 2008

31st Annual Macula Society Meeting, Palm Beach, Florida, March 26-29, 2008

  • Murray TG et al. Targeting Regional Hypoxia Enhances Retinoblastoma Tumor Control:  Use of 2-DG as a Novel Therapeutic Strategy

2008 AAO Mid-Year Forum, Wachington, DC, April 9 – 12, 2008

ARVO 2008 Annual Meeting, Ft. Lauderdale, Florida, April 27 – May 1, 2008

  • Moderator – Retinoblastoma I

Retinal Physician Symposium, Naples, Florida, 2008 – May 29-31, 2008

  • Murray TG et al. Adult Tumor Update
  • Murray TG et al. Surgery for DME

American Board of Ophthalmology, San Francisco, California, June 4 – 9, 2008

  •  Examiner

World Ophthalmology Congress 2008, Hong Kong, China, June 28 – July 2, 2008

  • Murray TG et al.  Macrophages and Blood Vessels in Retinoblastoma
  • Murray TG et al.  Visions for Better Therapy:  Preclinical Evidence
  • Panel Discussion – Retinoblastoma and Uveal Melanomas

Pediatric Retina, Strasbourg, France, August 27 – 30, 2008

  • Murray TG et al.  Antiangiogenic Therapy for Retinoblastoma: Effect of Tumor Burden and Dose Schedule in the Murine LH BETATAG Transgenic Model
  • Murray TG et al.  Tumor Microenvironmental Targeting Therapy Improves Retinoblastoma Tumor Control
  • Murray TG et al.  Vascular Targeting Increases Hypoxia in LHBETATAG Murine Retinoblastoma

Club Jules Gonin,St. Moritz, Switzerland, September 10 – 14, 2008

  • Murray TG et al.  Hypoxic Modulation Enhances Retinoblastoma Tumor Control:  A Novel Treatment Strategy

Retina Society Meeting,Scottsdale, Arizona, Sept. 25-28, 2008

  • Murray TG et al.  Intraoperative Echography Enhances Local Tumor Control and Long-term Survival for Brachytherapeutic Treatment of Uveal Melanoma

26th Annual Mtg of the American Society of Retina Specialists, Maui, HI, Oct 11-15, 2008

  • Murray TG et al.  Advances in Ocular Tumor Management – 2008
  • Recent Advancements in 532 Green Laser Technology and Probe Enhancement:  Clinical assessment and laboratory evaluation

American Academy of Ophthalmology, Atlanta, GA, November 8-12, 2008

  • Murray TG et al.  Laser & Laser Probes
  • Murray TG et al.  Ocular Treatment Options for Retinoblastoma
  • Murray TG et al.  Hypoxia Modulation Improves Vessel Targeting in Retinoblastoma
  • Poster: Retinal Detachment Rates and Visual Acuity Outcomes of Patients Undergoing Pars Plana Vitrectomy for Retained Lens Fragments
  • Poster: Bevacizumab Reduces Vision Loss From Radiation Retinopathy After Iodine-125 Plaque Brachytherapy for Posterior Uveal Malignant Melanoma
  • Poster: Nosocomial Acute-Onset Postoperative Endophthalmitis at a University Teaching Hospital
  • Murray TG et al.  Immunology and retinoblastoma

American Society of Retina Specialists, Strategic Planning Retreat, January 23- 25, 2009

Association of Pediatric Retinal Specialist, Duck Key, Florida, Jan. 29 – Feb. 1, 2009

  • Murray TG et al. Advances in Retinoblastoma Management:  Vascular targeting improves tumor control in combined modality therapy

Angiogenesis, Exudation and Degeneration 2009, Miami, Florida, February 21, 2009

  • Murray TG et al. The Economics of Anti-VEGF Therapy in an Academic Practice

7th International Spectralis Symposium (ISS), Miami, Florida, February 27-28, 2009

  • Murray TG et al. Advanced OCT/Autofluorescence Imaging of Posterior Choroidal Tumors

37th Annual Aspen Retinal Detachment Society Meeting, Snowmass Village, Colorado, March 1-5, 2009

  • Murray TG et al. Complex Case Management – A Roundtable Review

American Society of Retina Speicalists, Chicago, Illinois, April 18, 2009

2009 Mid-Year Forum, Washington, D.C., April 22-25, 2009

Vitreoretinal Update 2009, Miami, Florida, May 1-2, 2009

  • Murray TG et al. Choroidal  Melanoma:  Pearls Long After the COMS
  • Murray TG et al. Vascular Biology of Retinoblastoma: Implications for Novel Treatments

ARVO Annual Meeting, Ft. Lauderdale, Florida, May 3-7, 2009

  • Murray TG et al. Role of Matrix Metalloproeinase-9 in LH BETA Tag Retinal tumor Growth
  •  Murray TG et al.  Optical Coherence Tomography in a Murine Retinal Detachment Model.
  • Murray TG et al.  Recent Advancements in 532 Green Laser Technology and Probe Enhancement: Clinical Assessment and Laboratory Evaluation.
  • Murray TG et al.  Retinoblastoma Tumor Burden: Effect of Macrophage Depletion on LHBETATAG Retinal Tumor Growth.
  • Murray TG et al. Vascular Targeting Agent and Glycolytic Inhibitor Combination Therapy Decreases Tumor Burden in Advanced LHBETATAG Murine Retinoblastoma.
  • Murray TG et al. Chemotherapy Plus Cyclosporine A for the Treatment of Intraocular Retinoblastoma.
  • Murray TG et al. Fundus Pigmentation in Treatment-requiring Retinopathy of Prematurity (ROP).
  • Murray TG et al. Nosocomial Acute-Onset Postoperative Endophthalmitis at a University Teaching Hospital (1995-2008)
  • Murray TG et al.  Acute-Onset Endophthalmitis Following Clear Corneal Cataract Surgery: A 12-Year Review (1996-2008)

SW Regional AAO Tristate Meeting, Flagstaff, Arizona,  May 15-17, 2009

  • Murray TG et al. Advanced Tumor Management 2009:  The End of a Remarkable Decade
  • Murray TG et al. Age Related Macular Degeneration 2009:  Imaging and Targeted Vascular Therapy Revolutionize Treatment Success

American Board of Ophthalmology Oral Examinations, Chicago, Illinois, June 5-7, 2009

  • Invited Special Examiner

Pediatric Grand Rounds, July 28, 2009

  • Murray TG et al. Advances in Pediatric Retinoblastoma Management: Application of Translational Research

Michigan Society of Eye Physicians and Surgeons 41st Annual Conference, Mackinac Island, Michigan, August 14 – 16, 2009

  • Murray TG et al. Age Related Macular Degeneration 2009:  Imaging and Targeted Vascular Therapy Revolutionize Treatment Success
  • Murray TG et al. Advanced Tumor Management 2009:  The End of a Remarkable Decade

Alcon Consultant Meeting, Chicago O’Hare, Illinois, August 20 – 21, 2009

2009 Chicago AVTT and Fellow’s Forum, Chicago, Illinois, August 21-23, 2009

  • Moderator:    Diabetes Mellitus and Retinal Vascular Diseases
  • Murray TG et al. Combined Small Gauge Vitrectomy with Phacoemulsification
  • Murray TG et al. The Role of anti-VEGF Therapy in the Treatment of Uveal Melanoma
  • Murray TG et al. Retinoblastoma Update

International Congress of Ocular Oncology,Cambridge, United Kingdom, September 8-12, 2009

  • Moderator:  Angiogenesis
  • Murray TG et al. Ocular Tumor Vascular Development: Tumor Angiogenesis and Regionalization of Vascular Progression

Combined Meeting:  ASRS, Macula Society and Retina Society, New York City, New York, Sept. 30 – Oct. 4, 2009

  • Poster : Focal, Periocular Delivery of 2-Deoxy-D-Glucose Alone and as an Adjuvant to Chemotherapy for Treatment of Advanced Retinoblastoma

Subspecialty Day and American Academy of Ophthalmology Annual Meeting, Oct. 22-27, 2009

  • Discussion Group Leader:  V11.25- and 23-Gauge Instrumentation for Vitrectomy
  • Murray TG et al. Intra-operative OCT Analyzing the BPEI Academic, Hospital-based Practice With a Focus on Profitability and Efficiency
  • Murray TG et al. Vascular Targeting in Ocular Oncology
  • Murray TG et al. Management of radiation maculopathy and papillopathy

ASRS – Strategy & Business Plan Group Meeting II, Rosemont, IL, January 8-10, 2010

Angiogenesis Meeting, Miami, Florida, February 20, 2010

  • Murray TG et al. Pharmacotherapies for Ocular Tumors

38th Annual Aspen Retinal Detachment Society Meeting, Aspen, Colorado, March 6-13, 2010

ASRS Mid Year Board Meeting, Chicago, Il, April 17, 2010

Retinal Physician Symposium, Paradise Island, Bahamas, April 21-24, 2010

  • Murray TG et al. Dislocated IOL’s:  Exchange, Reposition, Suture
  • Murray TG et al. Treatment algorithm for retinal vein occlusion

ARVO Annual Meeting, Ft. Lauderdale, Florida, May 2-6, 2010

  • Poster: T Cells Targeting Cancer Stem Cells in Uveal Melanoma
  • Paper: Retinoblastoma Molecular Genomics: Regional Differences in the Molecular Genomics Expression Following Treatment With 2-Deoxy-D-Glucose in LHBETATAG Retinal Tumors
  • Paper: Supraselective Intra-Ophthalmic Artery Chemotherapy: Evaluation of Treatment Related Complications in Advanced Retinoblastoma
  • Moderator -  Poster Session # 279, Session Title: AP – Retinoblastoma
  • Poster: Retinal Findings in Patients With Aicardi Syndrome
  • Poster: Retinoblastoma Tumor Burden Control: Periocular m-TOR Inhibitor Rapamycin Decreases Tumor Burden in Advanced LHBETATAG Murine Retinoblastoma
  • Poster: Regional and Temporal Differences in the Genetic Expression of LHBetaTAg Retinoblastoma Tumors
  • Paper:  Intraoperative Spectral Domain Optical Coherence Tomography (SD-OCT) Imaging of Complex Pediatric Retinal Disease
  • Moderator: Poster Session – Tumors and Clinical/Experimental Study
  • Poster: Open Globe Injuries: Computerized Tomography and Echography in Clinical Management

World Congress of Ophthalmology,Berlin, Germany, June 5-9, 2010

  • Moderator: Retina:  Diagnostics 1
  • Murray TG et al. Angiogensis in retinoblastoma
  • Murray TG et al. Combined MIVS 23 Guage Vitrectomy and Phacoemulsification in the Management of Complex Macular Pathology

ASRS Annual Meeting, Vancouver, Canada,  August 28 – Sept. 2, 2010

  • Murray TG et al. Surgical Comparison of Combined Sutureless Microincisional 23 versus 25+ Gauge Vitrectomy Surgery (MIVS) with Concomitant Phacoemulsification
  • Poster:  Supraselective Intra-arterial Chemotherapy Utilizing Ophthalmic Artery Delivery for Advanced Retinoblastoma

Retina Consultant and Advisor Mtg, Chicago, IL, September 9-10, 2010

Retina Society, San Francisco, CA, Sept. 23-26, 2010

  • Murray TG et al. 10,000 Intravitreal Injections: Analysis of impact on the Ocular Oncology Service at BPEI

American Academy of Ophthalmology Meeting,Chicago, IL, Oct.15-16, 2010

  • Moderator: Oculoplastics Original Papers:  Tumors

Club Jules Gonin 2010, Kyoto, Japan, Nov. 3-6, 2010

  • Poster: Periocular Combined 2-DeoxyGlucose with Carboplatin Chemotherapy increases Retinoblastoma Tumor control through Hypoxia Modulated enhancement of Chemotherapy

Association of Pediatric Retinal Surgeons Meeting, February 24-27, 2011

  • Murray TG et al. Supraselective Intra-Artrial Melphalan Chemotherapy in Retinoblastoma: Evolving Treatment Schedules and Dosing Regimens

39th Aspen Retinal Detachment Society, Snowmass, Colorado, March 5-9, 2011

  • Murray TG et al. Retinoblastoma:  Unique Diagnosis and Treatment Paradigms in 2011
  • Murray TG et al.  Uveal Melanoma:  Applications of High Resolution Imagining and Adjunctive Intravitreal Therapy Enhance Cure in 2011

11th Antwerp Vitreoretinal Course, Antwerp, Belgium, March 17-19, 2011

  • Murray TG et al.  Combined Phaco-Vitrectomy
  • Murray TG et al.  Dislocated Nuc Fragments/Displaced IOL
  • Murray TG et al.  Wide Field Viewing
  • Murray TG et al.  Comparison of 23 / 25 G MIVS Systems

ARVO 2011, Fort Lauderdale Convention Center, Ft. Lauderdale, Florida, May 1-5, 2011

  • Murray TG et al.  A Novel, Oral, Non-invasive Method Of Delivery For The Glycolytic Inhibitor 2-deoxy-d-glucose In The Treatment Of Retinoblastoma”
  • Moderator:  Retinoblastoma II, Poster Session

Kresge Eye Institute’s 56th Annual Clinical Conference Update in Clinical Ophthalmology, Detroit, Michigan, June 17-18, 2011

  • Murray TG et al.  Novel Therapeutic Strategies for Advanced Retinoblastoma

Masters in Ophthalmology 2011, Palm Beach, Florida  33480, June 24-26, 2011

  • Murray TG et al.  Ocular Oncology Update: 2011

Advanced Vitreoretinal Techniques & Technology (AVTT) Symposium (and CPE Vitreoretinal Fellows Program), W Chicago City Center Hotel, August 12-14, 2011

  • Murray TG et al.  Practice Efficiency:  How to Manage “Quality” Care in

Today’s World

  • Murray TG et al.  Vitrectomy and Cataract Surgery-Combined or Sequential Surgical Approach?  Are Outcomes Different?
  • Murray TG et al.  Microincisional Vitrectomy Surgery (MIVS)

Instrumentation-Tips and Tricks

  • Murray TG et al.  HD Video-Operative Approaches to Better Video

29th American Society of Retina Specialist Annual Meeting, Boston, Massachusetts, August 20-24, 2011

  • Murray TG et al.  “Implications of 23/25+ Gauge Microincisional Vitrectomy Surgery with Adjunctive Intravitreal Steroid Pharmacotherapy”
  • Murray TG et al.  “Clinical Experience case study – ERM”

American Academy of Ophthalmology Meeting, Convention Center, Orlando, Florida, October 21-25, 2011

  • Moderator: Retina 2011: The Magical World of Retina – Beauties and the Beasts: Retinoblastoma Roundtable
  • Moderator:  Advancements in Surgical Technology:  A Retina Case Review
  • Moderator: Murray – Roundtable Number:B470 Update on Ocular Oncology 2011

XVth Biannual Meeting of the International Society of Ocular Oncology, Buenos Aires, Argentina, November 14-17, 2011

  • Murray TG et al.“mTOR targeting in combination with chemotherapy: Upstream regulation of anaerobic glycolysis to target the chemoresistant cell population in RB”
  • Dr. Murray (Panelist) – RETINOBLASTOMA PANEL 30 RBp127
  • Poster: Treatment modulation in retinoblastoma tumorigenesis and its impact on tumor burden
  • Murray TG et al. A novel, oral, non-invasive method of delivery for the glycolytic inhibitor 2-deoxy-D-glucose in the treatment of Retinoblastoma.
  • Murray TG et al. Intra-arterial melphalan dosing regimens for the treatment of retinoblastoma


Member Of:

  • American Academy of Ophthalmology
  • American Board of Ophthalmology
  • Fellow American College of Surgeons